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ABSTRACT 
 
THE CONNECTION BETWEEN MARIJUANA, CIGARETTE SMOKING AND METABOLIC SYNDROME 
AMONG ADULTS IN THE UNITED STATES 
 
By 
BARBARA A. YANKEY   
 MARCH 24, 2017 
 
Under the direction of Ike S. Okosun, PhD 
 
 
Background: Alcohol, marijuana and tobacco are the most common recreationally used 
substances in United States (US). However, unlike alcohol and tobacco, marijuana is an illicit 
substance. The increasing support for reclassification of marijuana as legal substance 
necessitates investigating its effect on health. These studies seek to examine the relationship 
of marijuana and tobacco with metabolic syndrome (a precursor of cardiovascular diseases - 
the primary cause of morbidities and mortalities). 
Method: Data from 2011 public-use linked mortality file of the National Center for Health 
Statistics, Centers for Disease Control and Prevention, and 2005-2006 & 2011-2012 US National 
Health and Nutrition Examination Survey was used to estimate the effect of marijuana and 
tobacco on metabolic syndrome. Odds ratios from logistic regression analyses were determined 
using four main diagnostic criteria for metabolic syndrome. Odds ratios were compared using: 
National Cholesterol Education Program Adult Treatment Panel III, World Health Organization, 
European Group for the study of Insulin Resistance and International Diabetes Federation 
definitions of metabolic syndrome. Hazard ratios (HRs) for cardiovascular mortality were 
estimated using cox proportional hazard regression. 
Results: Each year of marijuana use was associated with increased odds of metabolic syndrome 
[OR=1.05 (95% CI: 1.01, 1.09)] and hypertension [OR=1.04 (95% CI: 1.01, 1.07)]. Each additional 
year of cigarette smoking was associated with increased odds of hypertension [OR=1.03 (95% CI: 
1.00, 1.06)] and hyperglycemia [OR=1.03 (95% CI: 1.01, 1.05)]. Adjusted HR for hypertension 
mortality for marijuana users compared to non-marijuana users was 3.42 (95% CI: 1.20, 9.79) 
and 1.04 (95% CI: 1.00, 1.07) for each year of marijuana use. 
Conclusion: Prolonged years of marijuana use was associated with increased odds of metabolic 
syndrome and hypertension irrespective of the criteria used to define metabolic syndrome. Our 
results also indicate that marijuana use is associated with increased risk for hypertension 
mortality. The association between prolonged use of marijuana and risk of cardiovascular 
morbidities and mortalities requires further investigation whilst developing global public health 
policies regarding legalization of marijuana use. 
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PREFACE 
Initiation and continual use of recreational substances, is a complex process. Science continues 
to investigate, project, inform and protect the populace from the deleterious effects of 
substance use. The National Institute on Drug Abuse states that “In reality, drug addiction is a 
complex disease, and quitting usually takes more than good intentions or a strong will. Drugs 
change the brain in ways that make quitting hard, even for those who want to.” 
Michael D. Lemonick in his article on the science of addiction opens with the statement, “For a 
species wired for survival, we have an odd habit of getting hooked on things that can kill us.” 
My dissertation was inspired by the many scenes of struggle as I travelled each day to school. I 
could hear the cry for help, feel the need for health, the yearning for love, see the hand of 
disparities. The question on my mind was simple; Why? Is it the search for joy? Is it curiosity? Is 
it neglect? Is it the lack of knowledge or is it deception that drives initiation of substance use? I 
came to the conclusion that the power still lies in knowledge; knowing the truth about the 
effect of any substances on our system. The saying has been from of old: “For lack of 
knowledge, people perish” 
I find the words of Pope Francisco powerful for anyone struggling with substance use and ill 
health. “You can have defects, be anxious and irritated sometimes. Live, but do not forget that 
your life is the biggest company in the world. Only you can prevent your life from going into 
decline. There are many who will appreciate, admire and love you. I would like you to 
remember that, being happy is to stop being a victim of the problems and rather become an 
actor of history itself. Use failure to sculpt serenity.” 
“Quia non habuit scientiam gens pereat” 
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CHAPTER 1 
 
Literature Review 
 
Marijuana and Cigarette Smoking as Recreational Substances 
 
Recreational substances are substances that have the potential to alter consciousness 
with a resultant pleasurable feeling. Reasons ascribed to the use of recreational substances span 
primarily from actual relieve of depressing symptoms to curiosity and social acceptance. Some 
recreational substances are commonly regarded as drugs because of their effect on the central 
nervous system. They are classified as legal, illegal or controlled depending on their psychoactive 
properties. 
Tobacco (Nicotiana species) and Marijuana (Cannabis species) are two common 
recreational substances whose main route of administration is smoking. Currently in the United 
States, apart from alcohol, tobacco and marijuana are the most common substances of abuse 
especially among adolescents (Latimer & Zur, 2010). The use of marijuana in adults is also 
increasing especially among adults aged 25 years and above. 
Smoking is a general term that describes the process whereby active substances are 
delivered into the bloodstream via the lungs after inhaling smoke from burnt dried leaves. 
Smoking is associated with certain cultures and practices and has been practiced way back in 
5000 BC; it currently is a common route of recreational drug use. 
Smoking is one of the leading causes of preventable death worldwide and a reversible 
and modifiable factor for several morbidities. Smoking induces several physiological responses 
that are not only carginogenic but cardiotoxic as well; research shows that smoking aggravates 
atherogenesis (McGill, 1988). Smoking seems to find a way of sustaining its popular social 
 2 
 
practice despite evidence of its detrimental effects on health. Research conducted by Doll and 
Hill initiated evidence into the carcinogenic effects of tobacco smoking on the lungs (Doll & Hill, 
1950) and ultimately the first surgeon’s general report on smoking and health in 1964 (Smoking 
& Health, 1964). 
Smoking is hazardous to every organ of the body and the benefits of smoking cessation 
interventions cannot be overstated (Anthonisen et al., 2005; Eriksen, Mackay, & Ross, 2013; 
Kottke, Battista, DeFriese, & Brekke, 1988; Lemmens, Oenema, Knut, & Brug, 2008; Prochaska, 
Delucchi, & Hall, 2004; West & Shahab, 2010). A review of the lung health study demonstrated 
that smoking cessation reduces mortality from both lung cancer and coronary heart disease 
(Anthonisen et al., 2005). Smoking cessation also improves lipid metabolism and cardiometabolic 
factors (Gastaldelli, Folli, & Maffei, 2010). Most of these studies assessed tobacco smoking, 
however research on the health effects of marijuana smoking is now evolving. 
 
 
Recreational Substance Use in the United States 
 
In the first century BC, the tobacco plant was used for medicinal, religious, and 
recreational purposes (Newton, 2010). After several years of use, the deleterious effect of 
tobacco on health and economic growth cannot be overstated and the impact of public health 
measures towards smoking cessation and successes cannot be understated. The current 
inclination towards legalization of marijuana questions the possibility of a replay of the journey 
with tobacco (Falkowski, 2014). 
The CDC reports that 17.8% of adults in the US were current smokers in 2013 with a 
greater prevalence among men (20.5%) than women (15.3%). The highest current smoking rates 
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were among non-Hispanic Multi-racials (26.8%) and non-Hispanic American Indians/Alaska 
Natives (26.1%) with lowest rates among non-Hispanic Asians (9.6%). 
Marijuana is classified as a Schedule I controlled substance under Federal law (Digest, 
2014). Schedule I substances under the Federal Controlled Substances Act (CSA) are considered 
as having a high potential for abuse and not having any currently accepted medical use in 
treatment, consequently its use is reserved for very limited circumstances. Notwithstanding, 
several States approve medical marijuana use and two States have legalized marijuana for 
recreational use. 
The World Health Organization (WHO) reports that the worldwide annual prevalence of 
cannabis use is about 2.5%. The National Institute on Drug Abuse (NIDA) estimates that in the US 
prevalence of current cannabis users aged 12 years and older, rose up to 7.3% in 2012 from 5.8% 
in 2007. This escalation is attributed to the current trend towards legalization of marijuana. 
As at 2013, 18 US states and the District of Columbia permitted medical use of marijuana, 
with Colorado and Washington permitting its recreational use. Contributing factors to the 
current move to legalize marijuana include the medical use of marijuana (Hoffmann & Weber, 
2010). Additionally, some research support the argument that decriminalization of cannabis has 
the potential to make law enforcement resources available to control certain trafficking activities 
without increasing cannabis abuses (Single, E. et al., 2000). Research on the effects of chronic 
use of marijuana is exigent if marijuana will universally be used recreationally. 
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Tobacco 
 
Tobacco use is a very important modifiable lifestyle associated with preventable ill health 
and premature mortality. Tobacco smoking is a major risk factor for many chronic diseases that 
affect primarily the heart, liver and lungs. Tobacco is obtained mainly from the leaves o the plant 
Nicotiana tobacum, though there are over 70 species of the plant. There are many formulations 
of tobacco; common ones are cigarettes, cigar, snuff and kreteks to name a few. 
The main active ingredient in tobacco is nicotine which is a stimulant. The primary mode 
of administration is smoking. Nicotine binds to cholinergic nicotinic receptors and promotes the 
release of several neurotransmitters. Nicotine is addictive and induces tolerance (Benowitz, 
1998); this plays a factor in its chronic and incremental use among some people. This could also 
play a competitive role with individual smoking cessation volition. Nicotine’s stimulant activity on 
the sympathetic nervous system leads to increase in blood pressure and heart rate. High doses 
can also lead to hypotension. 
The popularity and spread of tobacco use was facilitated by major tobacco companies 
who used several marketing strategies to make tobacco use especially smoking enticing and 
even acceptable among women (for whom smoking was frowned upon). Smoking rates in the US 
rose up to about 42% in the 1960’s and dropped starting 1965 after the first surgeon general’s 
report on smoking and health to about 20.6% in 2008 (Dube, Asman, Malarcher, & Carabollo, 
2009) and about 19.3% among adults aged 18 years and above (Control & Prevention, 2011). 
The WHO estimates that in the early 1990’s about 1.1 billion people aged 15 years and 
above worldwide smoked; equivalent to a third of the global population. The gender rates were 
about 47% of males and 12% of females. It was estimated that the number of smokers may 
 5 
 
increase to about 1.64 billion by 2030 with a resultant increase in factors of poor health as well 
as mortalities if no measures were taken to discourage smoking. Smoking cessation programs 
have contributed greatly in reducing smoking prevalence rates. Overall global smoking 
prevalence among people aged 15 years and above fell to 29% in 1995 (Jha, Ranson, Nguyen, & 
Yach, 2002). In 2012, the estimated worldwide age-standardized prevalence of smoking among 
this cohort was 31% for men and 6.2% for women, however there are regional disparities in 
these smoking rates (Ng et al., 2014). 
Doll and Hill demonstrated associations between smoking and lung cancer (Doll & Hill, 
1950), several other studies which ensued confirmed similar findings. A 34 year follow up of 
Framingham cohorts who were 30-62 years when they entered the study demonstrated that 
cigarette smoking was associated with lung and cardiovascular disease: lung cancer, stroke, 
ischemic heart attack etc. (Freund, Belanger, D'Agostino, & Kannel, 1993). It is an established 
fact that smoking is associated with several health hazards (Eriksen et al., 2013; Slama, 2012). 
Smoking is also characterized by premature and high mortality and cessation reverses ill health 
(Jha et al., 2013). 
Across all studies the benefits of smoking cessation is emphasized. Smoking cessation has 
immediate and important benefits to all who stop smoking even after a short time, leads to 
longer life span, decrease the risk for lung cancer and cardiovascular diseases (Critichley & 
Capewell, 2007; General, 1990; Jha et al., 2013; Taylor Jr, Hasselblad, Henley, Thun, & Sloan, 
2002). 
There is evidence that tobacco use is associated with weight reduction and this has the 
potential of discouraging smoking cessation among people who seek to fight or prevent obesity. 
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Smoking may increase basal metabolism or reduce appetite and consequently may result in 
reduced intake of food (Louis-Sylvestre, 1993). Weight gain and obesity are however not just a 
direct cause of food or increased caloric intake. Obesity has multifactorial components and more 
research is needed in this area to fully elucidate the effect of tobacco use not only on weight but 
on the classification of obesity and among different populations. 
Results of research on tobacco and weight distribution or classification are actually 
 
not conclusive; some report that smoking increases abdominal obesity (Chiolero, Faeh, Paccaud, 
& Cornuz, 2008) others that it decreases weight (Klesges, Meyers, Klesges, & LaVasque, 1989) 
and others report the associations are weight definition dependent (Potter, Pederson, Chan, 
Aubut, & Koval, 2004). Since body weight shares integrate properties with metabolic syndrome 
and several chronic diseases, one area of interest is the effect of tobacco use (which is also 
connected to several diseases and controversial with weight) on the metabolic syndrome. 
Much as this is an understudied area for tobacco, available literature shows that smoking 
has nonlinear relationships with factors of metabolic syndrome especially among moderate 
smokers, but heavy smoking of 20 cigarettes or more daily leads to adverse levels of metabolic 
factors which approach linearity (Fontes, Moshammer, & Elmadfa, 2012). Research shows that 
smoking and even levels of serum cotinine consistent with environmental tobacco smoking is 
associated with metabolic syndrome (Sun, Liu, & Ning, 2012; Weitzman et al., 2005). Tobacco 
smoking is also associated with the lipid components of the metabolic syndrome; 
hypertriglycerideamia (Oh et al., 2005; Reynolds et al., 2011), low HDL (Chen et al., 2008; Oh et 
al., 2005). 
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Smoking causes inflammation; it increases the production of pro-cytokines, reduces 
levels of anti-inflammatory cytokines (Arnson, Shoenfeld, & Amital, 2010) and increases 
pathologic levels of inflammation-sensitive proteins like alpa1-antitripson,fibrinogen etc. which 
are associated with cardiovascular problems (Lind et al., 2004). Inflammation is a precursor to 
several factors of the metabolic syndrome. 
Smoking also reduces glucose tolerance and plasma insulin levels and demonstrates a 
dose dependent relationship (Janzon, Berntorp, Hanson, Lindell, & Trell, 1983). A large cohort 
study conducted by Will J. C. et al., and other prospective studies show that smoking is 
associated with the incidence of diabetes and this was likely dose dependent as well (Kawakami, 
Takatsuka, Shimizu, & Ishibashi, 1997; E. B. Rimm et al., 1993; Eric B Rimm, Chan, Stampfer, 
Colditz, & Willett, 1995; Will, Galuska, Ford, Mokdad, & Calle, 2001). 
Even though the relationship between smoking and body weight is complex, tobacco 
smoking is most likely associated with increasing rates of metabolic syndrome. The NCEP ATP III 
has emphasized that with increasing rates of obesity, metabolic syndrome is likely to have a 
greater attributable impact than tobacco on premature death from coronary artery diseases (E. 
S. Ford, Giles, & Dietz, 2002; S. Grundy et al., 2002; Program, 2001). This makes smoking and 
metabolic syndrome very important subjects for public health if global health goals must be 
achieved. 
 
 
Marijuana and Medical Marijuana 
 
Marijuana or cannabis is a leafy flowering plant that embraces three species; Cannabis 
sativa, Cannabis indica and Cannabis ruderalis. Though cannabis is used orally, common route of 
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administration is smoking after which it is readily absorbed in the lungs. Cannabis has 
psychoactive properties and is a popular recreational substance because it induces relaxation 
and euphoria to some extent. 
Cannabis is also used medically in some settings; it has been used to relieve chronic and 
neuropathic pain as well as nausea where conventional medications fail to provide relieve of 
symptoms. Dronabinol and nabinol are medications of cannabis indicated for chemotherapy 
associated nausea and vomiting. They are also used to manage anorexia associated with weight 
loss in patients who have acquired immune deficiency syndrome. The use of cannabis is 
however also associated with psychotropic and other adverse health effects. 
The active ingredients of cannabis are known as cannabinoids; the major psychoactive 
ingredient is Delta-9 tetrahydrocannabinol (THC). Cannabis exerts its effect on the 
endocannabinoid system where they act on cannabinoid receptors. Cannabinoid receptors are 
stimulated by endocannabinoids which are endogenous ligands. Cannabinoid receptors 1 (CB1) 
and 2 (CB2) were discovered during the 1990’s and this has since increased interest in research 
of cannabinoids. Apart from the brain, cannabinoid receptors and endocannabinoids are present 
in peripheral tissues. 
Absorption of cannabis can be erratic and differs in individuals. The plasma half-life of 
cannabis is 20-30 hours. Cannabis can be detected in the urine for up to two months in a heavy 
user but a few days in a rare user. In up to moderate doses, cannabis increases sympathetic 
activity leading to tachycardia and increased cardiac output. At high dosage, cannabis increases 
parasympathetic activity resulting in bradycardia and hypotension. Both the sympathetic and 
 9 
 
parasympathetic effects of cannabis can be life-threatening especially among people who have 
underlying cardiac problems (Ghuran & Nolan, 2000; Olson, Anderson, & Benowitz, 2007). 
Both CB1 and CB2 are involved in regulation of energy balance, appetite, insulin 
sensitivity and lipid metabolism (Blüher et al., 2006; Engeli & Jordan, 2006; Pagotto, Marsicano, 
Cota, Lutz, & Pasquali, 2006). Research support that the endocannabinoid system as well as 
chronic smoking of cannabis are associated with metabolic irregularities like abdominal obesity 
and insulin resistance (Blüher et al., 2006; Di Marzo, 2008; Kunos, 2007; Muniyappa et al., 2013) 
as well as cardiovascular function (Cota, 2007; Pacher & Steffens, 2009). 
Upon stimulation of CB1 receptors, the liver and adipose tissues respond through 
lipogenesis, lipid accumulation and impairs insulin secretion and function or induces pancreatic 
beta cell death (Kim et al., 2012; Sarker & Maruyama, 2003). Apart from endocannabinoids, the 
psychoactive agent in cannabis, THC also stimulates CB1 and can induce glucose intolerance. 
Cannabinoid receptors are important targets in pharmacology for managing obesity 
(Bellocchio, Mancini, Vicennati, Pasquali, & Pagotto, 2006). Stimulation of CB1 receptors 
increases appetite; the principle of managing obesity by using the pharmacologic agent 
Rimonabant which is a CB1 receptor antagonist. Rimonabant is however central acting and 
causes neuropsychological effects, thereby preventing its approval in the US and subsequent 
withdrawal from several markets. CB2 receptors are also involved in metabolic changes 
associated with diet, however stimulation of CB2 receptors improve glucose tolerance 
(Bermudez-Silva et al., 2007) and seem to work in the reverse of CB1 stimulation. 
Chronic use of cannabis no doubt is associated with metabolic health. A major problem 
with the use of medical cannabis is standardization of the dose as well as an acceptable 
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formulation. There are about 60 cannabinoids in cannabis aside so many other active substances 
that have not been studied. Absorption of the active ingredients in cannabis is erratic and 
specific to an individual’s physiologic make up which can lead to overdosing and poisoning. Also 
the effect of the active ingredients in cannabis can be contradicting and unpredictable. 
The endocannabioid system is involved in metabolic regulation, is a major target of 
interest for managing obesity and indiscriminate use can lead to chronic detrimental health. It is 
important to consider the long term effect of chronic and liberal use of marijuana on metabolic 
and cardiovascular health among populations. 
 
 
Metabolic Syndrome and its Genesis 
 
Metabolic syndrome is the co-existence of delineated clinical and biochemical risk factors 
that increases the propensity of having a cardiovascular disease or event by about three fold 
(Isomaa et al., 2001). The genesis of work on factors associated with metabolic syndrome dates 
back. It is noteworthy that the masterpiece of the Father of pathology, Joannes Baptista 
Morgagni - ‘De sedibus et causis morborum per anatomen indagata’ published in 1765, initiated 
the description of correlation between visceral obesity, high blood pressure and cardiovascular 
disorders (Morgani, 1765). In 1947 the French physician Dr. Jean Vague published his work on 
the finding that abdominal obesity is associated with diabetes and cardiovascular diseases 
(Vague, 1947). He introduced the terminology android obesity to describe this condition. 
During the late 1960s through 1970s, advances in technology and availability of 
epidemiologic data permitted varied research on the metabolic syndrome. Several terminology 
were used to describe the co-existence of its risk factors; metabolic trisyndrome and notable 
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among them plurimetabolic syndrome. In 1988 Dr. Gerald Reaven described the common 
clustering of dyslipidemia, hypertension and hyperglycemia as Syndrome X (Reaven, 1988). He 
noted that Syndrome X was a multiple risk factor for cardiovascular diseases and implicated the 
role of insulin resistance in Syndrome X, hence the term insulin resistance syndrome. 
 
 
Metabolic Syndrome and Criteria for Research 
 
The risk factors for metabolic syndrome are extensively documented, however a unifying 
definition remains a challenge. The risk factors, its combinations or cut of points are varied for 
different deliberative bodies; World Health Organization (WHO), European Group for the Study 
of Insulin Resistance (EGIR), National Cholesterol Examination Program, Adult Treatment Panel III 
(NCEP ATPIII) and recently criteria by the American Heart Association/National Heart, Lung and 
Blood Institute (AHA/NHLBI) and the International Diabetes Federation (IDF). The new IDF 
definition for metabolic syndrome is the presence of central obesity (ethnic specific waist 
circumference values) and any two values of the following: hypertriglyceridemia, elevated blood 
pressure, raised fasting plasma glucose or reduced levels of high density cholesterol. A previous 
diagnosis of diabetes or medications for any of the listed conditions is also included. The 
definition by NCEP ATPIII is commonly used in clinical practice because the factors are more 
practical to measure. 
 
 
Metabolic Syndrome, Epidemiology and Risk Factors 
 
The worldwide prevalence of metabolic syndrome ranges from 10% to about 84% 
depending on the definition used for metabolic syndrome or demographic composition of the 
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population (Desroches & Lamarche, 2007; Kolovou, Anagnostopoulou, Salpea, & Mikhailidis, 
2007). The National Health and Statistics Report shows that during 2003 to 2006, based on 
NCEP/ATPIII guidelines, the prevalence of MetS in the United States was about 34% among 
adults aged 20 years and above. In the general US population, the age adjusted prevalence of 
MetS was estimated to have reduced from 25.5% in 1999 to 22.9% in 2010, however this 
pattern of decrease is not evident in the prevalence of risk factors of the individual components 
of MetS (Beltrán-Sánchez, Harhay, Harhay, & McElligott, 2013). 
Obesity especially abdominal obesity is a major risk factor for metabolic syndrome, and 
consequently a component of metabolic syndrome (Bray, 2007; Despres & Lemieux, 2006). 
Obesity induces neuroendocrine abnormalities which affects various metabolic activities leading 
to diabetes and cardiovascular diseases (Björntorp, 1992). Surging rates of obesity among 
populations are associated with increasing MetS prevalence and incidence of chronic diseases 
(Eckel, Grundy, & Zimmet, 2005; James, Rigby, & Leach, 2004). 
Dyslipidemia, insulin dysfunction, and high blood pressure are the other determinants of 
metabolic syndrome. Apart from increases in waist circumference, elevations in triglycerides and 
blood pressure and are most attributable to increase in rates of metabolic syndrome especially 
among adults (Earl S Ford, Giles, & Mokdad, 2004). Dyslipidemia promotes atherogenesis, which 
is a major path to aberrations in cardiovascular integrity (S. M. Grundy, 1997). The role of insulin 
dysfunction and hypertension in metabolic syndrome is demonstrated through their actions on 
the sympathetic nervous system, leading to endothelial abnormalities and poor cardiovascular 
function (Mendizábal, Llorens, & Nava, 2013). 
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Among demographic characteristics, increasing age also predisposes one to a higher 
tendency for metabolic syndrome. Progress in age is associated with several pathological 
processes in the human system (S. M. Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004) 
including changes in tissue energy metabolism that could lead to lower resting metabolic rate 
with advanced age (Fukagawa, Bandini, & Young, 1990). 
Several studies show that MetS is more prevalent among men than women and this is 
attributed to android or central obesity (Regitz-Zagrosek, Lehmkuhl, & Weickert, 2006), which is 
more of a fat distribution pattern among men. Compared to gynoid obesity, android obesity 
leads to cardiovascular diseases. The anti-atherosclerotic property of estrogen also plays a 
protective role in the lower rates of MetS among women. This is evident in that fact that rates of 
MetS increase among post-menopausal women in whom estrogen levels are low (Regitz- 
Zagrosek, Lehmkuhl, & Mahmoodzadeh, 2007; Tong et al., 2005). Yet, among those with MetS, 
men still carry higher prevalence of cardiovascular diseases and mortality from other causes 
irrespective of underlying diagnosis of diabetes or cardiovascular disorder (Kurl et al., 2006; 
Lakka et al., 2002). 
Social economic factors like education and income can change the relation between 
MetS and gender (Loucks, Rehkopf, Thurston, & Kawachi, 2007). Education and increased 
income generally acts favorably on metabolic factors. Among women those who are educated 
are generally less likely than those who are not, to have the MetS; however this pattern is not 
necessary so among men. This also applies to increased income; low income to poverty ratio is 
associated with high MetS rates among women (Loucks et al., 2007). The impact of other factors 
like marriage and place of birth on MetS are of research interest. 
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Racial and gender specific differences exist with respect to MetS (Ervin, 2009; E. S. Ford 
et al., 2002). Non-Hispanic White females are less likely than non-Hispanic Black and Mexican 
American females to have MetS, whereas non-Hispanic White males are generally more likely 
than non-Hispanic Black males to have MetS (Ervin, 2009). Ethnic differences in MetS rates, has 
partly been explained by diet (Beydoun et al., 2008), socioeconomic and lifestyle factors which 
contribute to obesity (Cossrow & Falkner, 2004) as well as genetic factors (Firmann et al., 2008) 
or an integration of the environment with genetic factors (Benyamin et al., 2007). Other 
physiologic factors like insulin resistance seem more prevalent among Hispanics, leading to a 
higher rate of MetS among them (Li et al., 2006). 
Among lifestyle factors, whereas reduced physical activity and fatty diet are evidently 
associated with a higher risk for metabolic syndrome, the effects of alcohol and tobacco on MetS 
are not conclusive (Lee, Jung, Park, Rhee, & Kim, 2005; Mayer, Newman, Quesenberry, 
Friedman, & Selby, 1993; Eric B Rimm et al., 1995; Sacco et al., 1999; Santos, Ebrahim, & Barros, 
2007). Yoon et al. however, conclude that heavy alcohol consumption is actually associated with 
increased likelihood of having metabolic syndrome as a whole or some factors of the MetS 
especially central obesity and hypertension (Y. S. Yoon, Oh, Baik, Park, & Kim, 2004). 
 
 
Cigarette Smoking, Marijuana Use and Metabolic Syndrome 
 
Although tobacco use has declined substantially in the United States, it remains the 
second-leading cause of total deaths and disability. The perception of lower risk associated with 
varied forms of substance use, can potentially lead to re-engagement or encourage initiation of 
substance use. For example flavored cigarettes enticed adolescents to initiate smoking. The 
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wrong notion that e-cigarettes are less harmful also encourages cigarette smoking. Legalization 
of marijuana backed by information, that marijuana is beneficial or not associated with certain 
diseases, or conditions that carry grave consequences on morbidity, disability and mortality like 
metabolic syndrome, could potentially threaten public health gains, if ultimately it is 
demonstrated not to be so. The scientific community, has the responsibility to protect the health 
of the public, through sharing evidence-based information, or at least in the absence of evidence 
exercise restraint in divulging information that could potentially be harmful in the long term. It is 
still important to document and support tested evidence of any benefits of substance use. 
Because recreational substances affect the brain and have psychoactive properties, if it 
must be prescribed for ailments, monitoring must be available. It is necessary to invest resources 
to investigate and address any benefits or harms associated with substance use. If marijuana 
must be permitted for recreational use, the health system must be in readiness for the varied 
aspects of the consequences of liberal recreational use of a substance that is psychoactive, has 
erratic distributions and effects among different individuals and is comparatively understudied in 
contemporary times. It is important to invest in investigations on marijuana use and the primary 
cause of disabilities, morbidities and death, in the interest of sustaining public health gains in 
cardiovascular disease prevention among the population and achieving sustainable health for 
the populace. 
Cardiovascular Morbidities and Mortalities 
 
Cardiovascular disease (CVD) and stroke continue to be responsible for huge health and 
economic burdens both in the US and globally, irrespective of the declining rates of mortalities 
from CVDs. The American Heart Association report that a decline of 28.8% was observed in the 
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US from 2003 to 2013. The 2013 overall rate of death attributable to CVD was 222.9 per 100,000 
Americans with gender and racial-ethnic differences (Mozaffarian, Benjamin, Go, Arnett, Blaha, 
Cushman, Das, de Ferranti, Després, & Fullerton, 2016). Non-Hispanic black males had the 
highest death rates (356.7 per 100,000) compared to 246.6 per 100,000 for non-Hispanic Black 
females. Generally, males had a higher death rate than females. The death rates were 269.8 for 
males and 184.8 for females (Mozaffarian, Benjamin, Go, Arnett, Blaha, Cushman, Das, de 
Ferranti, Després, & Fullerton, 2016). 
The decline in CVD deaths are attributed to clinical and behavioral interventions 
especially increase in physical activity, good diet and smoking cessation as well as surveillance on 
cardiovascular health and its associated risk factors. Generally current cigarette smoking rates 
among adults have declined. In 2014, the prevalence of adult current smokers was 16.9% 
compared to 24.1% in 1998. Irrespective of the declining rates of cigarette smoking, CVD deaths 
due to tobacco use are still ranked high; together smoking and exposure to secondhand smoke 
are attributable for about one third of coronary heart disease mortalities (Mozaffarian, 
Benjamin, Go, Arnett, Blaha, Cushman, Das, de Ferranti, Després, Fullerton, et al., 2016). 
Hypertension is a major risk factor for cardiovascular, cerebrovascular and renal diseases. 
Hypertension is an underlying factor for most cardiovascular and cerebrovascular mortalities as 
well as disabilities and as such poses a major health burden. Hypertension is attributable for 
almost 50% of all global deaths from stroke. Hypertension prevalence is expected to increase by 
about 60% on the global level by 2025 if no measures are taken to prevent the demographic 
expansion of hypertension among populations (Kearney et al., 2005). Interventions leading to 
controlled blood pressure is thus important. It is noteworthy that about 17.3% of all 
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hypertension cases are undiagnosed, and this carries grave consequences for those affected. 
Apart from smoking cessation, the decline in stroke mortality is also a result of controlling 
diabetes mellitus, hypercholesterolemia and hypertension. 
 
 
Economic costs of cardiovascular disease and substance use 
 
The American Heart Association (AHA) report that, estimated annual cost for CVD and 
stroke during 2011-2012 was $316.6 billion, including $193.1 billion in direct costs (hospital 
services, physicians and other professionals, prescribed medications, home health care, and 
other medical durables). During this period, indirect cost associated with lost future productivity 
due to premature deaths from cardiovascular diseases and stroke was $123.5 billion, the 
heaviest economic burden compared to all other diseases (the estimated direct cost for all 
cancer was $88·7 billion in 2011). The cost associated with addressing substance use in the US is 
estimated at $600 billion dollars annually (Abuse, 2015) 
 
 
Theoretical Basis of Substance Use and Prevention 
 
Substance Abuse and Mental health Services Administration (SAMHSA) report that in 
2014, about 10.2% of Americans used an illicit substance in the past 30 days. They were aged 12 
years and above. This percentage was higher than that observed each year from 2002 to 2013. 
Marijuana use is adjudged the main driver of the increased prevalence of illicit substance use, 
22.2 million of the total 27.0 million people used an illicit substance in the past 30 days 
(adjudged current users). 
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Bandura’s social cognitive theory (Bandura, 1999) explains the initiation and maintenance of a 
given behavior and has been used to explain smoking and drug related behaviors, as well as 
incorporated in plans to assist prevention or cessation of substance use. By this theory, 
cognitive, environmental and behavioral factors interplay to define substance use. 
Cognitive factors explain how the individual’s mental capability and disposition allows 
him/her to understand the effect of substance use on his/her system. The emotional coping 
responses to the effect of substance use, the individuals behavioral capacity under the influence 
of substance use as well as self-efficacy. Overall, outcome expectancies play a role in substance 
use. If the individual expects beneficial outcomes from substance use, they are likely to start or 
continue using substances. If the individual expects to have cure of an ailment from using 
substances, he/she is likely to use it. Medical marijuana proponents attest to the fact that they 
benefit from using marijuana, for example in treating severe vomiting or pain, that responds to 
no other analgesics. People may smoke cigarettes because they find that it relieves their stress. 
At the same time, people do abstain from tobacco or drugs after experiencing very bad effects of 
substances. For example someone who suffers a cardiac arrest after substance use, and would 
likely not want to use the substance again, having come to face the reality of possible death in 
connection to substance use. For some self-efficacy plays a major role in deciding strongly to 
abstain and giving up to the detrimental effects of the substance. The mental capability plays a 
major factor. At times genetic dispositions can explain cognitive behaviors with regard to 
substance use, whether an individual’s use of substances is predominantly because of dictates 
ingrained in the genes. 
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The environment is a major determinant of substance use. Environmental factors may 
enhance or prevent substance use. Living in an environment where substance use is prevalent or 
is the norm can support the use of substances. Generally people who live in environments where 
substance use is prohibited or where laws prevent the use of substances are not likely to initiate 
or continue the use of substances. Peer use of illicit substances or recreational substances can be 
a major environmental factor. Policies that allow or disallow the use of substances can also be a 
factor for substance use. For example, banning smoking in public areas, prevents smoking in 
those areas even if an individual is a heavy smoker. He/she will have to look for the right 
environment to smoke. Alternately, bars that allow smoking for example will attract not only 
smokers, but continuation of smoking activity which an individual may have stopped for some 
time because of enabling environment. 
Behavioral factors considers the individuals reactions to conditions in the environment or 
inputs from the environments. The individual is likely to use available information on marijuana 
use to make decisions whether to use marijuana or not. Information and education play very 
important roles in the choices we make. The duty of health professional is to make evidence based 
information available in a way to help individuals make informed decisions on their health. If 
marijuana use is beneficial like food, the information must be made available, if the use of 
marijuana is detrimental the information must be made available. Underlying each of these factors 
are constructs of the socio cognitive theory. The idea that marijuana use is safe seems to be 
assimilated well by a majority of the public and in some cases even among health-care 
professionals. This has contributed to the support for legalization of marijuana use not only 
medicinally but recreationally. 
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Constructs of the socio cognitive theory are behavioral capability, reciprocal determinism, 
emotional coping responses, outcome expectations, self-efficacy, collective efficacy, observational 
learning, incentive motivation, facilitation, self-regulation and moral disengagement. 
Behavioral capability considers the basic knowledge an individual has on substance use and 
the skills necessary to avoid substance use initiation or quit substance use. For example knowledge 
on the biological effects of marijuana on the human system, knowledge about the nature of 
marijuana and other substances, its use and adverse effects, helps individuals to make decisions 
on its use. Skills necessary indulging or avoiding marijuana use depends on the knowledge. To a 
large extent, health professionals must make information on substance use available to target 
groups and the populace in general to help control substance use. 
Reciprocal determinism, considers the interaction between individuals’ behavior and the 
environment. Whilst the social environment affects individuals’’ behavior, the individual’s 
behavior or actions also affects the environment in which he/she operates or chooses to live. 
Whether people choose to live in environments that support marijuana use or live in environments 
that do not support marijuana use depends on this interplay. Is it likely that states that legalize 
recreational marijuana use will attract people who are prefer to use marijuana or is it likely that 
people who live in states that legalize recreational marijuana are likely to accept and adopt the 
use as well as put in more measures to sustain policies that support marijuana use and protect 
people who use marijuana? 
Emotional coping responses address the responses to environmental and emotional 
stimulations or stressors. Coping responses are targeted towards achieving a mental wellbeing or 
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physical wellbeing, however, these responses can be negative or positive depending on the 
individual’s cognitive functions. An individual who is addicted to substances is likely to become 
confrontative if he/she is denied access to substances. Dependence on addictive substances is a 
major problem for health systems but has been capitalized by the respective companies as a 
sales strategy because it ensures the continuous use of these products irrespective of the 
adverse effects. Yet others harmed by substance use seek social support and enroll in 
rehabilitation programs. Others are self-controlling enough in the face of being temptation to 
avoid substance use, or control its use. Several coping mechanisms like distancing and positive 
reappraisal have been described (Sudraba et al., 2015). 
Outcome expectations describes an important factor in substance use behavior. 
 
Generally when people expect to have health benefits from a product, they are more likely to 
support its use and use it. Marijuana has been described as harmless in some publications, and 
people who expect not to be harmed by using marijuana will most likely use marijuana for some 
purpose. Medical marijuana is another reason why proponent s of marijuana use support its 
legalization. The outcome expectations of marijuana use is a major subject of contemporary 
debate. Yet others may use substances as an escape from reality. People who expect harms from 
the use of substances are likely to avoid using them. If business entities expect gains from sales 
of marijuana, they are likely to support its legalization and promote its sale. If state legislators 
expect to curtail illegal sales of marijuana and reduced criminal activities with marijuana 
legalization, they are likely to legalize marijuana use. 
Self-efficacy is the confidence or belief an individual has in performing certain activities to 
achieve an expected outcome. This is a very relevant construct of substance use abstinence, 
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initiation, continuation or cessation. The level of self-efficacy determines the amount of energy 
or resources an individual or system will invest in performing an activity to achieve a set 
outcome. 
Self-regulation is an individual’s ability to perform an activity. An individual may strongly 
to decide quitting smoking or not use marijuana or any substances. Self-regulation involves how 
an individual plans to attain health or benefits from an action either through avoiding situations 
that may promote substance use, or staying strong and avoiding substance use even when it’s 
available. Strategies used in self-regulation include goal setting, self-monitoring, self-reward, 
self-instruction, social support enlistment and feedback or evaluation. 
Incentive motivation is the strategic use of rewards for achieving a set goal for example 
for not smoking for ten days, and punishments like withdrawal of some privileges for non- 
achievement of set goals. Motivational incentives have been used to assist people continue 
cessation programs, for example by awarding them prices for attending programs or not using 
substances or presenting urine samples for investigation to affirm abstinence from substance 
use (Stitzer, Petry, & Peirce, 2010). 
Observational learning includes involves role modelling, observing the outcomes of the 
behavior of others and making informed decisions to abstain from a detrimental activity based 
on positive role modelling. Cues can be used in observational modelling to reinforce behavior or 
prevent certain behaviors. For example explicit pictures of harms associated with tobacco use on 
cigarette packages prevents people from smoking. 
Facilitation involves the provision of resources and tools to assist in positive behavior. 
 
Public health educators and other health care professionals play an important role in facilitation. 
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Availability of rehabilitation centers and medications to help manage and prevent substance 
abuse are important facilitators. The environment can also serve as a positive or negative 
facilitator. Environments that promote or support substance use can be negative facilitators. 
Collective efficacy is the combined force of a group to help each other achieve goals. 
Alcoholic Anonymous (AA) is a social group aimed at helping those who use alcohol heavily to 
stay sober or avoid heavy drinking through character building and spiritual support (Hunt & 
Azrin, 1973). When communities build solid trust, social capital and share healthy expectations, 
they can avoid crimes and unhealthy behaviors (Farmer, 2014). 
Moral disengagement concerns a way of action which ignores the harm that can be 
caused to others through substance use. For example, individuals may neglect the effect of 
second hand smoking by smoking in public places. They may neglect the harm they can cause to 
others by using psychoactive substances and driving. Moral disengagement can be challenging 
force in substance use, especially considering the harm it can cause others who do not engage in 
unhealthy lifestyles. Not educating people on the harms of substance use, and supporting the 
use of substances that could potentially be harmful to people, especially those are not self- 
efficacious can be classified moral disengagement. 
Constructs of the theoretical basis of substance use, is strongly tied to the socio- 
ecological model of health: individual, interpersonal, organizational, community and policy levels 
(Sallis, Owen, & Fisher, 2008). Each level of the socio-ecological model plays an important role in 
substance use and in the prevention of substance use. Science, the health community and social 
community must consider the health risks associated with recreational cannabis use and 
implement measures to protect the health of society. 
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Current evidence supports strategies to improve cardiovascular health. A three pronged 
strategy to improve cardiovascular health, include a) individual –focused approach which target 
lifestyle changes and treatment approaches, b) healthcare systems approach, which involves 
resources to improve health behaviors and health care as well as encouragement, facilitation 
and rewards for efforts by healthcare providers and patients towards health improvement and c) 
population approach which target lifestyle and treatment among various populations. 
 
 
Limitations in Research 
 
Research on marijuana use and in combination with metabolic syndrome is evolving. Data 
on marijuana use among all relevant age groups is scarce especially among the youth and 
elderly; this limits the population coverage that can be investigated for marijuana use and its 
effect on health. 
Most research find no significant associations between marijuana use and metabolic 
syndrome, whilst others present results showing that marijuana use is associated with reduced 
values of some components of metabolic syndrome like blood glucose (Penner, Buettner, & 
Mittleman, 2013). 
While these studies have stated some limitations others have questioned the design of 
the studies. Most studies on marijuana and metabolic syndrome are cross-sectional because the 
interest in this relationship is now evolving and data availability is limited. Longitudinal research 
on the relationship between marijuana and metabolic syndrome is scarce. 
A major challenge with assessing marijuana use is the definition of marijuana use. Some 
studies use reported marijuana use as ever use of marijuana, use of marijuana in the past 30 
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days. The NHANES has variables that describe marijuana use based on having ever used 
marijuana, marijuana use in past 30 days, number of joints of marijuana used, age at first use of 
marijuana, and more recently (2011-2012), whether one has used marijuana regularly for the 
past year. Unlike cigarette smoking, the status of marijuana use has not been explicitly defined in 
literature. Also, information on cotinine, the active metabolite of nicotine from tobacco is 
publicly available for analysis, but that of marijuana is not. This poses limitations in quantifying 
marijuana use in research. 
In assessing metabolic syndrome, definitions vary widely in literature because different 
deliberative bodies have different criteria for metabolic syndrome. This poses a challenge even in 
interpreting surveillance reports. The reported prevalence of metabolic syndrome is varies 
depending on the definition used. Cutt-off points for components of metabolic syndrome are 
also not unified. 
Cardiovascular effects of marijuana is based principally on experiments with delta 
tetrahydrocannabinol (THC) the active ingredients of marijuana. This is principally on animal 
models and administered by other routes instead of smoking, unlike tobacco which has been 
studied extensively in real like situations among human subjects. 
Marijuana is known to have a chemical variability has not been studied extensively. The chemical 
variability of marijuana, coupled with individual variations in smoking behavior, poses challenges 
in presenting firm conclusions on results from studies on marijuana that have used uncontrolled 
smoking observations (Jones, 2002). High potency marijuana is becoming readily available and 
experiments on their effects with respect to health is limited. 
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Studies on the effect of acute and chronic use of marijuana on specific biologic functions 
including cardiovascular processes for example, atherosclerosis, lipid metabolism, endothelial 
function, clotting function, and its sequelae are limited. Studies on cardiovascular effects of 
marijuana among older people with existing cardiovascular or cerebrovascular disease are 
limited. Generally, there is a need for studies on mortalities associated with marijuana use 
among the populace as its recreational use becomes legalized. 
 
 
Statement of Purpose 
 
The use of recreational substances carries both health and economic consequences 
which if not addressed could ultimately challenge global health developmental efforts. It is 
integral for public health to investigate the varied health effects of the use of substances that 
gain legal and liberal use. Tobacco and marijuana are two recreational substances used 
commonly in the United States. Like tobacco, marijuana use could potentially gain global 
acceptance with time. Tobacco remains a legal substance even though its detrimental health 
effects have been proven extensively. Public health has undoubtedly achieved a lot in the area of 
smoking cessation by improve the health of individuals who smoke as well as those exposed to 
second hand smoking. 
According to the US Federal Law, The Controlled Substance Act of 1970; there is a 
penalty for any act of possessing, dispensing, and prescribing marijuana. However in 1996, some 
14 States (California, Alaska, Oregon, Washington, Maine, Hawaii, Colorado, Nevada, Vermont, 
Montana, Rhode Island, New Mexico, Michigan, and New Jersey) had an amendment to their 
state laws that allowed people who had been diagnosed by certified licensed physicians as 
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having debilitating medical conditions to use of marijuana as supportive therapy. Gradually 
marijuana is gaining support for legalization of its recreational use. 
A journey back in history recounts how research by Doll and Hill in 1950 found the 
association between smoking, lung cancer and heart disease (Doll, R. and Hill, A. B., 1950) after 
massive support for tobacco smoking. With great public health effort, research and legal battle, 
this ultimately led to the Tobacco Master Settlement Agreement (MSA) in 1998 to address 
tobacco related health-care costs. The current trend towards recreational use of marijuana could 
possibly be another journey down the trend. Research on possible adverse health effects of 
marijuana use is exigent. 
Our research seeks to add to the geminating interest in research on metabolic syndrome 
and substance use as an illuminating pathway to addressing recreational substance use and 
factors associated with cardio-metabolic diseases, a major cause of morbidity and mortality. The 
cardio-metabolic association with recreational substance use especially marijuana has not been 
studied extensively, and this will be an exploratory study to add to emerging literature on 
marijuana use. 
We used data from National Health and Nutrition Examination Survey (NHANES); a 
program purposed to evaluate the health and nutritional status of the United States population. 
We conducted bivariate and multivariate analysis to estimate the relationship between tobacco 
smoking and marijuana use and factors of/and the metabolic syndrome. Definition of metabolic 
syndrome has varying criteria by different deliberative bodies. We also assessed effect of using 
varying criteria to define metabolic syndrome on the relationship with tobacco smoking and 
marijuana use. 
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Our aim is to investigate the relationship between: 
 
A) Tobacco and Marijuana use and factors of/and metabolic syndrome: Very few studies 
have looked at especially the relationship between marijuana use and metabolic 
syndrome. With the burgeoning interest in marijuana use, empirical studies on its impact 
with metabolic activity can be a pathway for describing chronic disease concerns related 
to its use. 
B) Tobacco and marijuana use with metabolic syndrome using the different criteria for 
metabolic syndrome: Identifying a unified criterion for metabolic syndrome is still a 
challenge. Different authorities in health give different criteria and cut-offs for metabolic 
syndrome which could affect conclusions from studies. We plan to investigate the 
relationship of tobacco and marijuana smoking under the different criteria for metabolic 
syndrome and describe any differences in conclusion that may surface. 
C) Marijuana use and cardiovascular health: The detrimental effects of tobacco on 
cardiovascular health are well studied, however that of marijuana is currently scarce. We 
will examine the relationship between marijuana use and mortality from cardiovascular 
diseases using the NHANES public-linked mortality data. 
Research Question/Hypothesis 
 
Our research question of interest is: a) is recreational substance use (Tobacco or 
Marijuana) associated with the metabolic syndrome? b) Using the different criteria for metabolic 
syndrome, are there significant differences in diagnosis of metabolic risk between people who 
engage in use of these recreational substances and people who do not? c) Do the additional 
criteria for metabolic syndrome proposed by the International Diabetes Federation (IDF) tell a 
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different story among those who use recreational substance and those who do not? d) Is the 
use of marijuana associated with mortality from a cardiovascular disease? 
For the purpose of this study, we assume the hypotheses that: a) those who use/smoke 
tobacco and/or marijuana have increased odds for having risk factors of the metabolic syndrome 
than those who do not, b) the different criteria for metabolic syndrome equally predict 
metabolic risk factors among people who smoke tobacco or marijuana without significant 
differences, and c) marijuana use like tobacco use is associated with high risks of mortality from 
a cardiovascular disease. 
 
Data 
 
National Health and Nutrition Examination Survey (NHANES)  
 
National Health and Nutrition Examination Survey (NHANES) started in 1960 and is a major 
program of the National Center for Health Statistics (NCHS), under the Centers for Disease 
Control and Prevention (CDC). The aim of the survey is to assess the health and nutritional status 
of civilian noninstitutionalized US population. Since 1999, NHANES is a continuous program 
which uses interviews and physical examinations for its purposes to assess the health and 
lifestyle indicators of a nationally representative sample of about 5000 US adults and children. 
After modifying the sampling technique employed for several iterations of data collection, 
NHANES adopted a continuous “rolling” sample approach in 1999; selection is done through 
complex, multistage probability sampling. Each year, the survey is conducted in 15 counties 
across the US. Interviews are conducted by physicians and other healthcare professionals in 
participant’s homes and examinations conducted in a mobile center. 
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National Health and Nutrition Examination Survey (NHANES III) Linked Mortality File – Public-use 
File  
The NCHS has a mortality linkage to NHANES III. This linkage is with the death certificate data from the 
National Death Index (NDI). The linked mortality file provides information on mortality among NHANES III 
participants from 1988 to 2006. The mortality information is based on probabilistic match between 
NHANES III and NDI death certificate records. The linked mortality file has a public-use and a restricted-use 
file. The public-use file provides information on a limited set of mortality variables for adults of the 
NHANES III survey, whilst the restricted-use file has more detailed mortality information and mortality 
follow-up for children. 
The public-use linked mortality file has information on the mortality status of adult participants 
(CDC, 2015). Mortality information on participants is obtained from death certificates or probabilistic 
matching from the National death index (NDI). The NHANES coded causes of death occurring in the US 
before 1999 are based on the 9th revision of the International Statistical Classification of Diseases, Injuries, 
and Causes of Death (ICD-9) guidelines and cause of death occurring since 1999 on the 10th (ICD-10) 
revision. Causes of deaths occurring before 1999 were subsequently recoded into comparable ICD-10 
rubrics. All deaths are classified as due to diseases of the heart (001), malignant neoplasms (002), chronic 
lower respiratory disease (003), accidents-unintentional injuries (004), cerebrovascular diseases (005), 
Alzheimer’s diseases (006), diabetes mellitus (007), influenza and pneumonia (008), nephritis, nephrotic 
syndrome and nephrosis (009) and all other causes (010). Those assumed alive, ineligible for follow up, 
aged below 18 years or have no cause of death available are left blank and un-coded. 
 
Independent Variables 
Our main independent variables are a) marijuana use and b) tobacco use. Tobacco use is assessed under 
smoking-cigarette use whilst marijuana use is assessed under drug use by NHANES.  
For smoking, all participants aged 12 years and above are eligible. Participants aged 12 -19 years 
answered the questions at a mobile examination center using the Audio Computer-Assisted Self-Interviewing 
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(ACASI) system in English and Spanish. Participants aged 20 years and above answered the questions at 
home. They were interviewed by trained interviewers using the Computer-Assisted Personal Interviewing 
(CAPI) system. The ACASI and CAPI have built in consistency checks to reduce data entry errors. 
Participants who are aged 12 to 69 years are eligible to be asked about their lifetime or current drug use. 
The participants administer a drug use questionnaire during an interview at a mobile examination center 
(MEC).  In the publicly available data file, only information from participants aged 18-69 years are included. 
Adults aged 18 years and above self-administer the questions using Audio computer-assisted self-
interviewing (ACASI) system. The ACASI system allows respondents to listen to and answer questions at their 
own speed. If an answer is entered that is programmed to be an error in the system, the respondent is 
prompted by the system to correct the response before proceeding. Participants are reminded that their 
answers are strictly confidential. 
Smoking or Tobacco Use 
For smoking/tobacco use, participants were asked a) “have you smoked at least 100 cigarettes your 
entire life?” Answers given yes or no will be used for analysis, b) age at regular smoking, “How old were you 
when you first started to smoke cigarettes fairly regularly?” Answers in range of years. Those who have never 
smoked are coded as zero. Those who refused to answer or did not know were not included in the analysis, 
c) current and continued use of cigarettes, “do you now smoke cigarettes?” We will include the answers 
every day, some days or not at all. Current smokers are those who have smoked at least 100 cigarettes in 
their life time and still smoke either every day or some days.  
Marijuana Use 
For marijuana use, participants are introduced to the description of marijuana and asked about their use 
of marijuana. “Marijuana is also called pot or grass. Marijuana is usually smoked, either in cigarettes, called 
joints or in a pipe. It is sometimes cooked in food. Hashish is a form marijuana that is also called ‘hash.’ It is 
usually smoked in a pipe. Another form of hashish is hash oil. Have you ever even once used marijuana or 
hashish?”  We will only include participants who answered yes or no. Participants who refused to answer, or 
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said they did not know or any missing information will be excluded from the analysis. 
Other questions on marijuana use include a) age at first use of marijuana; “how old were you when you 
the first time you used marijuana or hashish?” Answers in range of values in years, b) regular use of 
marijuana; “have you smoked marijuana or hashish at least once a month for more than once a year?” 
Answered as yes or no, c) age at regular use of marijuana; “how old were you when you started smoking 
marijuana or hashish at least once a month for more than one year?” Answers in range of values in years, d) 
frequency of marijuana use; “during the time that you smoked marijuana or hashish, how often would you 
usually use it?” Answers are categorized as once a month, 2-3 times a month, 4-8 time a month, 9-24 times a 
month, or 25-30 times a month, d) number of days they used marijuana in a month; “during the past 30 
days, on how many days did you use marijuana or hashish?” Answered as a range of values, from 1 to a 
maximum of 30, e) number of pipes or joints smoked daily; “during the time that you smoked marijuana or 
hashish, how many joints or pipes would you usually smoke in a day?” Answered as 1per day, 2 per day, 3-5 
per day, or 6 or more per day.  
Control Variables 
In our model, we controlled for demographic and lifestyle variables that confound the relationship 
between our main independent variables and dependent variable. One drug question of interest is whether a 
participant had ever used any other illicit/recreational drug, since these could be used jointly with marijuana; 
“Have you ever used cocaine, crack cocaine, heroin or methamphetamine?” The answers were yes or no. We 
used this as a control variable, where it was found to be confounding in the relationship between marijuana 
and metabolic syndrome. 
Questions on demographic indicators are asked by trained interviewers at home using the CAPI system. 
Unlike those under16 years, who may need a proxy, participants who are 16 years and older are interviewed 
directly. They chose the language of preference, either English or Spanish. 
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Age 
Age is related to cardiovascular health and no doubt metabolic syndrome as well as substance use. Some 
age categories highlight this relationship. We used age as a dichotomous variable because of the effect of 
age transition on substance use and metabolic health based on literature. In the NHANES, participants are 
asked to give their age in years at the time of survey. 
Gender 
Gender differences affect cardiovascular health as well as smoking and substance use. Males generally 
are more likely to use recreational substances than women do. Hormonal factors affect the cardiovascular 
health of men and women differently.  Participants stated their gender as males or females. 
Education 
Education is related to metabolic syndrome factors and substance use. Generally, more educated people 
can afford healthier choices which positively affect cardiovascular health and this could be a confounder in 
our model. In NHANES, participants are asked “what is the highest grade or level of school you have 
completed or the highest degree you have received?” the answers are ranked as a) less than 9th grade, b) 9th-
11th grade (as well as 12th grade with no diploma), c) High school grade or GED or equivalent, d) some college 
or AA degree and e) college graduate or above. We included education at an in interval level to control for 
the effect of each level rise in education in the model. 
Race and Ethnicity 
           In NHANES, participants are asked to identify themselves with the race/ethnicity they belong. They are 
listed as Non-Hispanic Whites, Black, Asians, Mexican Americans, Other Hispanics and Multiracials/or people 
of Other-Race. We used race as dummy variables with Non-Hispanic Whites as the reference.  
Country of Birth 
We controlled for country of birth. This is dichotomized as born in USA or other. In the survey, 
participants are asked; “In what country were you born?” The responses are a) born in any of the 50 states of 
the USA or Washington DC and b) other (born in another country). Place of birth may be associated with 
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cardiovascular health, through the effectiveness of healthcare systems  available that target, investigate or 
control these conditions at an earlier stage in life. Generally, rates of obesity are also higher among people 
born in US and this impacts metabolic syndrome rates. With respect to smoking, epidemiologic data shows 
that the prevalence of smoking is quite high in the USA, even though it is dropping due to smoking cessation 
interventions. Also, prevalence of marijuana use is high in the USA. We include country of birth as a 
confounder with respect to cardiovascular and metabolic health. 
Income to Poverty Ratio 
We controlled for the ratio of family income to poverty (PIR). Income is a major factor for cardiovascular 
health and as well as substance use. Generally, having a higher PIR is associated to better cardiovascular 
health, because of affordability for healthcare services and healthier lifestyle choices including dietary 
choices. Also, people who have a low PIR may engage more in substance use than those with a high PIR. 
Several explanations have been given for this relationship and could be the vice versa; drug use leads to 
poverty people may lose their jobs, alternatively, people who find themselves living in poor environments 
are often surrounded by drug users and may easily obtain drugs on the streets and become substance users 
themselves for several reasons. In the NHANES, PIR is recorded as a range of values from 0-4.9 and 5 for 
those whose PIR are either 5 and above. Respondents report the total annual income for the entire family in 
dollars. With this information, the PIR is calculated using the Department of Health and Human Services 
(DHHS) poverty guidelines. No ratios are computed if income data is missing. We will use variable as a 
continuous variable and assess the effect of each point rise in PIR or interval variable of: 0 to 1.0, 1.1 to 2.0, 
2.1 to 3.0, 3.1 to 4.0, 4.1 to 4.9, and 5.0 and above. 
For lifestyle factors, we controlled for alcohol use, physical activity and diet including other drug use.  
Alcohol Use 
Participants are asked about their lifetime and past 12 months’ alcohol use, irrespective of the type of 
alcohol use. They are asked how often they had an alcoholic beverage in the past 12 months. We computed 
number of alcohol drinks per week and assessed on a continuous level. 
 35 
 
Physical Activity 
Participants are assessed for physical activity based on the Global Physical Activity Questionnaire (GPAQ). 
Participants are asked if apart from work and transportation activities, they engage in at least ten minutes of 
continuous a) vigorous or b) moderate recreational physical activity in a typical day. Those who respond no 
to moderate physical activity were classified as not physically active and those who respond yes as physically 
active. 
 
Statistical Analysis 
We conducted statistical analysis using SPSS and STATA packages.  
To estimate the relationship between factors of/metabolic syndrome and recreational substance use. 
We conducted bivariate and multivariate analysis. We estimated the odds ratios for having unhealthy levels 
for any factor of /the metabolic syndrome among those who smoke tobacco, marijuana or both. 
 Model of bivariate analysis: 
 Y
component of MetS
 = b
0
 + b
1
(cigarette smoking) 
  
 Y
component of MetS
 = b
0
 + b
1 
(marijuana use) 
 
 Y
component of MetS
 = b
0
 + b
1 
(cigarette smoking + marijuana use) 
 
 Y
MetS                         
 = b
0
 + b
1
(iv
1
) 
 
Model of multivariate analysis: 
  Y
component of MetS
 = b
0
 + b
1
(iv
1
) + b
2
(iv
2
) + ……+b
k
(iv
k
) 
 
   Y
MetS
 = b
0
 + b
1
(iv
1
) + b
2
(iv
2
) + ……+b
k
(iv
k
) 
 
   Note: iv = independent variable 
 
 36 
 
 
  
For analysis by different criteria for metabolic syndrome, we assessed how the different criteria alters 
our diagnosis of metabolic syndrome. We estimated the odds ratios for having metabolic syndrome among 
those who smoke marijuana or tobacco compared to those who do not and assessed if there are any 
differences based on the different criteria. 
Model for bivariate analysis by metabolic syndrome criteria: 
  Y
MetS(ATPIII)
  = b0 + b1(iv) 
  Y
MetS(WHO)   
= b0 + b1(iv) 
  Y
MetS(EGIR)    
= b0 + b1(iv) 
  Y
MetS(IDF)     
 = b0 + b1(iv) 
 
Model for multivariate analysis by metabolic syndrome criteria: 
  Y
MetS(criteria)
  = b0 + b1(iv) + b2(iv2) + ……+b
k
(iv
k
) 
 
To estimate mortality from a cardiovascular disease attributable to marijuana or tobacco use. We 
used Cox proportional hazard regression to estimate the effect of marijuana use on cardiovascular mortality. 
We estimated hazard ratios to describe the relative risk of having a cardiovascular associated mortality. We 
used Nelson-Aalen curves to describe findings. 
 
Model for survival analysis: 
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A cross-sectional analysis of the association between marijuana and cigarette smoking with metabolic 
syndrome among adults in the United   States 
Barbara N.A. Yankey MSc. Pharm, MPA, MPHa,*, Sheryl Strasser PhD, MPHb, 
Ike S. Okosun PhD, MPHa 
a Georgia State University, School of Public Health, Division of Epidemiology and Biostatistics, 140 Decatur Street, Suite 848, Atlanta, GA 30303, USA 
b Georgia State University, School of Public Health, Division of Health Promotion and Behavior, 140 Decatur Street, Suite 848, Atlanta, GA 30303, USA 
 
 
A R T I C L E       I N F O 
 
 
Keywords: 
Cannabis 
Marijuana 
Cigarette 
Tobacco 
Smoking 
Metabolic syndrome 
A B S T R A C   T 
 
Aim: To assess the relationship between marijuana use, cigarette smoking and metabolic syndrome 
among adults in the United States who reported they use marijuana or cigarettes in comparison to non- 
marijuana and non-cigarette users. 
Method: We conducted multiple logistic regression analyses using data from the 2011–2012 United States 
National Health and Nutrition Examination Survey to estimate relationships between cardio- metabolic 
risk factors and increasing years of smoking cigarette or marijuana use. Statistical adjustments were made 
for both demographic and endogenous factors related to recreational substance use. 
Results: Each year increase in marijuana use was signiﬁcantly associated with increased odds of metabolic 
syndrome (OR = 1.05; 95% CI: 1.01, 1.09), and hypertension (OR = 1.04; 95% CI: 1.01, 1.07) adjusting 
for both demographic and endogenous factors related to recreational substance use. Each year increase 
in cigarette smoking was  signiﬁcantly  associated  with  increased  odds  of  hypertension  (OR = 1.03; 
95% CI: 1.00, 1.06) and hyperglycemia (OR = 1.03; 95% CI: 1.01, 1.05) after adjusting for confounders. 
Conclusion: The results of this investigation suggest that increased years of marijuana or cigarette use are 
important factors in metabolic health; and consequently calls for the need to consider the potential 
negative effects of marijuana or cigarette for metabolic syndrome and its associated cardio-metabolic 
risk components. 
© 2016 Diabetes India. Published by Elsevier Ltd. All rights  reserved. 
 
 
 
1. Introduction 
 
Cigarette smoking and marijuana (cannabis) use are two 
common recreational drug behaviors in many societies including 
the United States (US). While cigarette smoking is a modiﬁable risk 
behavior that is often linked to several chronic diseases [1], little is 
known about the true relationship between marijuana use and 
chronic disease conditions [2]. In the US, public opinion for 
marijuana seems to be changing to legalization with respect to its 
use for recreational purposes [3,4]. The use of marijuana for 
medical reasons [5–7] has elevated public support for its 
decriminalization. It is of importance to public health that    the 
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burgeoning support for marijuana legalization as a recreational 
substance be supported by evidence and research. Indeed, the 
increase in support for recreational use of marijuana in the US calls 
for an understanding and proper documentation of the nature of 
the association between marijuana use and conditions associated 
with diseases that have high rates of morbidity and mortality, 
including metabolic syndrome (MetS). 
Metabolic syndrome is a complex disorder deﬁned by a cluster 
of interrelated factors that increase the risk of cardiovascular, 
atherosclerotic diseases and type 2 diabetes. Described originally 
by Hanefeld and Leonhardt [8] and popularized by Reaven [9], 
MetS remains a subject of considerable curiosity because of the 
complexity of the pathophysiology. The main components of MetS 
are abdominal obesity, elevated arterial blood pressure, dysregu- 
lated glucose homeostasis, and dyslipidemia [10]. 
In this study we examined the relationship of recreational 
substance use, speciﬁcally cigarette and marijuana with   MetS. 
 
http://dx.doi.org/10.1016/j.dsx.2016.03.001 
1871-4021/© 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved. 
Contents lists available at ScienceDirect 
 
Diabetes & Metabolic Syndrome: Clinical Research & 
Reviews 
journal homepage: www.elsevier .com/locate/d  sx 
S90 B.N.A. Yankey et al. / Diabetes & Metabolic Syndrome: Clinical Research & Reviews 10S (2016) S89–S95 
 
38 
 
 
While some research exist on the effect of cigarette use on MetS 
[11,12], very little exist on the relationship between marijuana use 
and MetS, including its components. An underlying reason for 
investigating the connection between marijuana and metabolic 
syndrome is that cannabinoid receptors (the cell membrane 
receptor for active constituent of marijuana) and endocannabi- 
noids (endogenous ligands) are present in the peripheral tissues 
that are involved in energy regulation and homeostasis [13–  15]. 
Importantly, Delta-9-tetrahydrocannabinol (THC), the main 
active constituent of marijuana, acts on these cannabinoid 
receptors [16]. If an important relationship between cannabis 
and metabolic syndrome exists, its explication may help to lessen 
the future burden of cardiovascular diseases. 
 
2. Data and method 
 
2.1. Data source 
 
This study used data from the National Health and Nutrition 
Examination Survey (NHANES). The NHANES is a major program of 
the National Center for Health Statistics (NCHS), under the Centers 
for Disease Control and Prevention (CDC) that assesses the health 
and nutritional status of the US population. Since 1999, NHANES 
enrolls approximately 5000 persons from 15 counties across the US 
yearly for interview and examination. The enrollment is based on a 
continuous nationally representative and complex sampling 
method. 
 
2.2. Inclusion criteria 
 
This study was restricted to participants of 2011–2012 
NHANES. Only subjects aged 20 years and above who responded 
to the question on our main independent variable, ‘‘Have you ever 
even once used marijuana or hashish?’’ were eligible for this study. 
 
2.3. Dependent variables 
 
Our main dependent variable is metabolic syndrome (MetS). 
We also analyzed each of the individual components of MetS 
separately. We classiﬁed MetS using deﬁnitions by the National 
Cholesterol Education Program, Adult Treatment Panel III (NCEP, 
ATP III) 2004 modiﬁcation, which adapts the International 
Diabetes Federation (IDF) deﬁnition for hypertension and diabe- 
tes. Participants considered as having hypertension had an 
average blood pressure above 130/85 mmHg or were on 
antihypertensive medication. We used an average of the recorded 
blood pressure readings as the value of an individual’s blood 
pressure for the purpose of our study. Details on blood pressure 
measurement are described (http://www.cdc.gov/nchs/ 
nhanes/nhanes2009-2010/current_nhanes_09_10.htm). Partici- 
pants with fasting plasma glucose of 100 mg/dl or on some 
antidiabetic treatment including insulin were coded as having 
diabetes. The NHANES has a detailed description of laboratory and 
examination  procedures  listed  on  (http://www.cdc.gov/nchs/ 
nhanes/nhanes2011-2012/manuals11_12.htm). Abdominal obe- 
sity was coded as yes for females with waist circumference of 
more than 88.0 cm and yes for males with waist circumference 
of more than 102.0 cm. Females with plasma High Density 
Lipoprotein Cholesterol (HDL-C) of less than 50 mg/dl and males 
with less than 40 mg/dl were coded as having low HDL-C. 
Hypertriglyceridemia was coded yes for all participants with 
plasma triglycerides of 150 mg/dl and above. Participants with 
three or more of the components of metabolic syndrome 
(abdominal obesity, hypertension, hyperglycemia, hypertrigly- 
ceridemia and low HDL-C) were coded as having metabolic 
syndrome. 
2.4. Main independent variables 
 
Participants who answered no to the question ‘‘have you ever 
used marijuana?’’ were categorized as never marijuana users. 
Those who answered yes (had ever used marijuana), and 
answered no to the question, ‘‘have you smoked marijuana or 
hashish at least once a month for more than a year?’’ were 
categorized as non-regular marijuana users and those who 
answered yes as regular marijuana users. Other questions on 
marijuana use include: Age at ﬁrst use of marijuana (‘‘how old 
were you the ﬁrst time you used marijuana or hashish?’’) and Age 
at regular use of marijuana (‘‘how old were you when you started 
smoking marijuana or hashish at least once a month for more than 
one year?’’). We calculated years of marijuana use by subtracting 
age at regular marijuana use from the current age of participants. 
Participants who were non-regular or never users had zero for the 
number of years of marijuana used. For quantity of marijuana 
smoked, participants answered the question: ‘‘during the time 
that you smoked marijuana or hashish, how many joints or pipes 
would you usually smoke in a day?’’ The answers were 1 per day, 
2 per day, 3–5 per day, or 6+ per day. We used this as the quantity 
of marijuana used per day and assigned never users or non-regular 
users ‘‘zero’’ use per day. 
Our other independent variable of interest is cigarette 
smoking. Participants were asked, ‘‘Have you smoked at least 
100 cigarettes your entire life?’’ We coded those who answered 
no as non-smokers. For current use of cigarettes, participants 
who said they have smoked at least 100 cigarettes in their entire 
life, were asked ‘‘do you now smoke cigarettes?’’  We  coded those 
who said not at all as past smokers and those who said every day 
or some days as current smokers (current smokers are those who 
have smoked at least 100 cigarettes in their life time and still 
smoke either every day or some days). To know the age at regular 
smoking, participants were asked, ‘‘How old were you when you 
ﬁrst started to smoke cigarettes fairly regularly?’’ We coded years 
of smoking cigarettes for those who have never smoked as zero 
and did the subtraction for current smokers. Those who refused 
to answer or did not know were not included in the analysis. 
 
2.5. Control variables 
 
For our control variables,  we  dichotomized  age  as  above 25 
years or below and compared with those above 25 years. This is 
based on the effect of this age transition on metabolic syndrome, 
speciﬁcally, aging and oxygen uptake during physical activity. 
Research shows that from age 25 years to age 65 years, the 
maximal intake of oxygen reduces by almost 5 ml per kg per min 
[17]. In analyzing the effect of our main independent variables on 
metabolic syndrome and its factors, we found it important to 
consider this factor. Gender was categorized as male and female. 
We compared other racial ethnic groups (Non-Hispanic Blacks, 
Mexican Americans, other Hispanics, Asians and other Races) with 
non-Hispanic Whites. We included education on an increasing 
level as laid down by NHANES (Tables 1a and 1b). We 
dichotomized physical activity as participation in at least 
moderate physical activity (at least 10 min of continuous daily 
recreational activity apart from all other activities) or not. 
 
2.6. Control variables endogenous to recreational substance use 
 
Married participants were compared to all other participants in 
other marital categories listed in NHANES. Poverty to income ratio 
was classiﬁed on an increasing level (Table 1a). Weekly frequency 
of alcohol intake as reported by participants was estimated and 
included in the model on an increasing level. Response to the 
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Table 1a 
Demographic characteristics of participants by cigarette smoking and marijuana use status. 
 
Variable Sample size, (%) Cigarette  smoking 
Status, % 
 
Marijuana use 
Status, % 
  
Current Past Never Regular Non-regular Never 
Gender 
Male 
 
1499 (50.87) 
 
28.88 
 
14.54 
 
52.29 
 
32.11 
 
25.77 
 
39.65 
Female 1552 (49.13) 19.01 18.83 66.44 20.03 28.44 54.21 
 
Race        
Non-Hispanic Whites 1113 (36.46) 31.09 20.49 48.43 32.70 33.51 33.78 
Non-Hispanic Blacks 793 (25.99) 25.00 11.74 63.26 31.48 25.66 42.86 
Mexican Americans 329 (10.78) 16.72 19.15 64.13 15.81 23.10 61.09 
Other Hispanics 281 (9.21) 18.15 19.22 62.63 19.57 21.71 58.72 
Asians 427 (14.00) 11.94 13.11 74.94 7.96 18.74 73.30 
Other Race 108 (3.54) 29.63 14.81 55.56 40.74 28.70 30.56 
Marital status 
Married 
 
1371 (44.94) 
 
18.67 
 
19.91 
 
61.42 
 
20.00 
 
27.52 
 
52.48 
Never married 920 (30.15) 23.18 11.64 65.18 28.48 28.26 43.26 
Widowed 42 (1.38) 35.71 23.81 40.48 35.71 23.81 40.48 
Divorced 275 (9.01) 33.09 22.18 44.73 33.45 29.82 36.73 
Separated 123 (4.03) 33.33 10.57 56.10 22.76 25.30 52.03 
Living with partner 320 (10.49) 36.56 14.37 49.06 39.81 20.06 40.13 
 
Country of birth        
USA 2154 (70.65) 28.84 16.77 54.39 34.06 31.88 34.06 
Other countries 895 (29.35) 12.51 16.54 70.95 7.26 15.31 77.43 
 
Education        
<9th grade 149 (4.88) 22.82 22.15 55.03 12.75 8.72 78.52 
9th to 11th grade 403 (13.21) 42.43 18.11 39.45 35.82 19.90 44.28 
High school graduate 620 (20.32) 33.28 16.64 50.08 33.12 21.65 45.23 
Some college/AA degree 1008 (33.04) 24.90 15.97 59.13 29.07 30.85 40.08 
:::College graduate 871 (28.55) 8.15 16.07 75.77 15.73 32.84 51.44 
Age groups (years)        
20–25 543 (17.80) 20.85 6.64 72.51 29.83 28.55 41.62 
26–35 758 (24.84) 26.25 15.17 58.58 29.50 28.04 42.46 
36–49 1015 (33.37) 24.14 16.85 59.01 22.76 26.80 50.44 
50–60 735 (24.09) 23.95 25.58 50.48 24.76 25.17 50.07 
 
PIR        
<1.00 753 (26.39) 34.79 13.94 51.26 32.49 24.10 43.41 
1.00–2.99 1048 (36.73) 27.79 17.19 55.01 28.91 24.24 46.85 
3.00–4.99 555 (19.45) 15.32 17.48 67.21 19.28 33.51 47.21 
>5.00 497 (17.42) 10.06 19.72 70.22 20.52 33.80 45.67 
Percentages are row percentages. Chi square tests (p-values not included in table) showed signiﬁcant differences among the various groups by smoking and marijuana use 
status. PIR = Family income to poverty ratio. 
 
Table 1b 
Clinical and laboratory characteristics of participants by cigarette smoking and marijuana use. 
 
Variable Sample size Overall percentage Current smoking 
Status, % 
 
Marijuana use 
Status, % 
 
 Current Past Never  Regular Non-regular Never  
Clinical examination          
High WC 2996 49.80 22.65 18.57 58.78*  25.49 26.43 48.09 
High blood pressure 3051 33.53 26.00 20.33 53.67***  26.13 26.03 47.85 
Laboratory investigation          
High FPG 3051 20.88 24.96 20.57 54.47**  25.47 25.63 48.90 
High Serum Triglycerides 3051 18.32 26.65 21.47 51.88***  26.12 28.09 45.80 
Low Plasma HDLC 3051 39.63 27.79 16.46 55.75***  24.75 26.66 48.59 
Components of MetS  Average ± SE        
Waist circumference, cm 1338 97.8 ± 0.8 98.4 ± 0.9 99.8 ± 1.8 97.1 ± 0.8*** 98.5 ± 1.4 97.7 ± 1.1 97.5 ± 0.8* 
SBP, mm Hg 1325 118.6 ± 0.8 121.7 ± 1.7 119.9 ± 1.6 117.0 ± 0.9*** 
 
120.3 ± 1.6 117.3 ± 0.9 118.2 ± 0.9* 
 
 
 
 
Tests of signiﬁcance for row percentages are based on chi-square tests, for continuous variables are F-tests and averages shown are weighted averages. WC, waist 
circumference; FPG, fasting plasma glucose; HDCL, high density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; *Signiﬁcance at <0.05; 
**Signiﬁcance at <0.01; ***Signiﬁcance at <0.001 for row differences. 
DBP, mm Hg 1325 71.9 ± 0.6 71.8 ± 1.0 73.9 ± 1.0 71.2 ± 0.7*** 72.0 ± 0.8 72.3 ± 0.8 71.5 ± 0.8 
FPG, mg/dl 1355 101.6 ± 1.1 102.2 ± 1.4 104.6 ± 3.3 100.6 ± 1.4 102.6 ± 2.9 101.5 ± 1.5 101.01 ± 1.2 
Serum triglycerides, mm/dl 1341 132.2 ± 6.4 149.1 ± 6.6 135.2 ± 9.8 124.8 ± 6.4*** 139.2 ± 8.1 124.2 ± 8.2 133.0 ± 9.1 
HDL  cholesterol, mm/dl 1342 51.7 ± 0.6 49.8 ± 1.3 52.3 ± 1.1 52.3 ± 0.5** 50.9 ± 1.2 52.1 ± 0.9 52.1 ± 0.6 
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2.7. Statistical methods 
 
We downloaded data using SPSS and analyzed with Stata/MP 
11.2 software package. We compared basic demographic and 
clinical variables by cigarette smoking and marijuana use status. 
Unadjusted and multivariate logistic regression analysis was 
used to determine the association between cigarette smoking and 
marijuana use with metabolic syndrome and its compo- nents. 
Emphasis was placed on the duration (years) of smoking 
cigarette and/or marijuana use. We applied the appropriate 
weights in both our bivariate and multivariate analysis. The 
model, adjusted for age, gender, education, poverty to income 
ratio, participation in at least moderate physical activity, weekly 
alcohol use, other illicit drug use (methamphetamine, heroin or 
cocaine), having had rehabilitation, marital status and having 
health insurance. We considered p-value below 0.05 as statisti- 
cally signiﬁcant. 
 
 
3. Results 
 
3.1. Demographic  and  clinical characteristics 
 
The total sample consisted of 3051 participants, 50.9% men and 
49.1% women with an average age of 38.7 ± 11.7 years (average 
weighted age was 39.6 ± 0.7, not shown in table) ranging from 20 to 
59 years. Overall 59.3% of study participants were nonsmokers, 
24.0% were current smokers and 16.7% were former smokers. 
Approximately 47.0% of study participants were regular marijuana 
users, 26.2% have never used marijuana while 27.0% were non- 
regular users of marijuana. Among those who were regular 
marijuana users, 47.7% were current cigarette smokers as well, 
25.7% were past cigarette smokers and 26.6% have no history of 
tobacco use (not shown in table). The demographic distribution by 
cigarette smoking or marijuana use status is shown in Table 1a. The 
prevalence and weighted averages of the components of metabolic 
syndrome are shown in Table 1b. Apart from fasting glucose, there 
are signiﬁcant differences in these factors by cigarette smoking 
status. Stratifying by marijuana use status shows signiﬁcant 
differences for systolic blood pressure and waist circumference. 
The prevalence of metabolic syndrome among all the study 
participants is 23.5%. 
3.2. Unadjusted results 
 
Unadjusted logistic regression shows that current smokers have 
an odds ratio of 1.43 (95% CI: 1.13, 1.81) for having high  blood 
pressure, and 1.61 (95% CI: 1.01, 2.55) for having high triglyceride 
levels than nonsmokers (Table 2). The unadjusted model for 
marijuana use shows that each year of using marijuana is 
associated with an odds ratio of 1.02 (1.00, 1.04) of having 
metabolic syndrome. A signiﬁcant increased odds with each year of 
cigarette smoking is observed for hypertension (OR: 1.03, 95% CI: 
1.02, 1.03), hypertriglyceridemia (OR: 1.03, 95% CI: 1.02, 1.04) and 
hyperglycemia (OR: 1.02, 95% CI: 1.00, 1.03). Each year increase in 
marijuana use is also associated with a signiﬁcant increase in odds 
for hypertension (OR: 1.01, 95% CI: 1.00, 1.02),  hypertriglycer- 
idemia (OR: 1.01, 95% CI: 1.00, 1.03) and hyperglycemia (OR: 1.02, 
95% CI: 1.00, 1.03) (Table 2). 
 
3.3. Adjusted results 
 
Multivariate logistic regression analysis adjusted for age, 
gender, education, participation in at least moderate physical 
activity, weekly alcohol use, income to poverty ratio, having health 
insurance, marital status, other illicit drug use and having had 
rehabilitation. Controlling for these factors, the odds ratio for each 
year increase of using marijuana is 1.05 (95% CI: 1.01, 1.09) for 
metabolic syndrome and 1.04 (95% CI: 1.01, 1.07) for hypertension 
(Table 3a). In this same model, each year of smoking cigarettes is 
associated with an odds ratio of 1.03 (95% CI: 1.00, 1.06) for 
hypertension as well as 1.03 (95% CI: 1.01, 1.05) for hyperglycemia. 
By marijuana use status, the results show signiﬁcant reduced odds 
for MetS (OR 0.23; 95% CI: 0.06, 0.90), hypertension (OR 0.31; 95% 
CI: 0.13, 0.70) and hypertriglyceridemia (OR 0.70; 95% CI 0.50, 0.99) 
among regular marijuana users compared to non-users (Table 3a). 
We did not ﬁnd signiﬁcant associations between smoking 
cigarettes or marijuana use and low levels of HDL in this analysis. 
Table 3b shows results for multivariate analysis separately among 
cigarette smokers and separately for marijuana users. 
 
4. Discussion 
 
Research supports the science that the endocannabinoid 
system as well as chronic smoking of cannabis is associated with 
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Table 2 
Unadjusted analysis of having metabolic syndrome or risky levels of components of metabolic   syndrome. 
Variable Cigarette, odds ratio (95% CI) Marijuana, odds ratio 
(95% CI) 
  
A. Years of smoking B. Smoking status C. Years of use D. Use status 
Metabolic   syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A, The relationship between each year increase in cigarette smoking with the listed variables; B, The relationship between current smoker or past smoker compared to non- 
smokers and the listed variables; C, The relationship between each year increase in marijuana use and the listed variables; D, The relationship between regular marijuana 
users or non-regular marijuana users and the listed variables. 
 1.00 (0.99, 1.02) Current 1.51 (0.80, 2.87) 1.02 (1.00, 1.04) Regular 1.01 (0.56, 1.84) 
 Past 1.64 (0.97, 2.79)  Non-regular 0.87 (0.67, 1.14) 
Abdominal obesity       
 1.01 (0.09, 1.01) Current 0.92 (0.66, 1.28) 1.01 (0.99, 1.02) Regular 0.81 (0.59, 1.11) 
  Past 1.11 (0.74, 1.66)  Non-regular 0.89 (0.70, 1.11) 
Hypertension  
1.03 (1.02, 1.03) 
 
Current 
 
1.43 (1.13, 1.81) 
 
1.01 (1.00, 1.02) 
 
Regular 
 
1.82 (0.57, 1.19) 
  Past 1.53 (0.94, 2.50)  Non-regular 0.94 (0.72, 1.23) 
Hyperglycemia  
1.02 (1.00, 1.03) 
 
Current 
 
1.46 (0.86, 2.48) 
 
1.01 (1.00, 1.03) 
 
Regular 
 
1.10 (0.52, 1.34) 
  Past 1.22 (0.69, 2.16)  Non-regular 1.01 (0.56, 1.41) 
Hypertriglyceridemia 
1.03 (1.02, 1.04) 
 
Current 
 
1.61 (1.01, 2.55) 
 
1.02 (1.00, 1.03) 
 
Regular 
 
1.21 (0.71, 2.07) 
 Past 1.40 (0.93, 2.11)  Non-regular 1.21 (0.80, 1.82) 
Low HDL cholesterolemia      
1.00 (0.09, 1.00) Current 1.28 (0.93, 1.75) 1.01 (0.99, 1.02) Regular 0.97 (0.65, 1.45) 
 Past 0.95 (0.63, 1.43)  Non-regular 0.88 (0.61, 1.27) 
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Table 3a 
Multivariate analysis of metabolic syndrome/components with years of cigarette and MJ use controlling for other risk  factors. 
 
 Metabolic SYN AO HPT HYPGLY HYPTRIG Low HDLC 
Marijuana use
1
 1.05 (1.01, 1.09) 1.03 (0.99, 1.07) 1.04 (1.01, 1.07) 1.01 (0.97, 1.05) 1.02 (0.99, 1.04) 1.03 (0.99, 1.06) 
Cigarette smoking
1
 1.00 (0.09, 1.00) 1.00 (0.09, 1.01) 1.03 (1.00, 1.06) 1.03 (1.01, 1.05) 0.99 (0.18, 5.45) 1.00 (0.09, 1.00) 
Regular MJ user 0.23 (0.06, 0.90) 0.45 (0.14, 1.43) 0.31 (0.13, 0.70) 0.61 (0.18, 2.08) 0.70 (0.50, 0.99) 0.53 (0.19, 1.44) 
Cigarette smoker 1.24 (0.96, 1.59) 0.93 (0.74, 1.17) 0.81 (0.49, 1.36) 0.74 (0.52, 1.04) 0.68 (0.33, 1.40) 0.97 (0.77, 1.23) 
MJ Quantity
2
 1.25 (0.80, 1.95) 1.05 (0.77, 1.41) 0.98 (0.75, 1.28) 1.17 (0.82, 1.67) 1.03 (1.01, 1.05) 1.07 (0.80, 1.43) 
Cigarette Quantity
2
 0.99 (0.90, 1.02) 0.98 (0.96, 1.00) 1.00 (0.97, 1.02) 0.99 (0.97, 1.02) 0.99 (0.96, 1.02) 1.01 (0.98, 1.03) 
Age 25+ 2.70 (1.60, 4.54) 2.75 (1.10, 6.84) 3.95 (2.06, 7.57) 2.68 (1.45, 4.97) 2.05 (1.01, 4.15) 1.41 (0.73, 2.73) 
Males 0.94 (0.58, 1.50) 0.28 (0.19, 0.42) 1.29 (0.87, 1.91) 1.81 (1.20, 2.72) 1.60 (1.06, 2.41) 0.84 (0.55, 1.26) 
Whites 1.08 (0.67, 1.73) 1.42 (0.99, 2.04) 1.08 (0.81, 1.45) 0.98 (0.72, 1.33) 1.16 (0.82, 1.65) 1.07 (0.70, 1.62) 
Education 0.83 (0.72, 0.94) 0.82 (0.67, 1.00) 0.93 (0.79, 1.11) 0.89 (0.76, 1.04) 1.06 (0.88, 1.28) 0.95 (0.76, 1.19) 
PIR
3
 0.87 (0.76, 1.01) 0.91 (0.84, 0.99) 0.92 (0.82, 1.03) 1.01 (0.90, 1.14) 0.95 (0.85, 1.06) 0.91 (0.78, 1.05) 
Insured 1.33 (0.76, 2.35) 1.07 (0.73, 1.58) 1.77 (1.02, 3.07) 1.22 (0.91, 1.63) 1.00 (0.60, 1.66) 1.40 (0.93, 2.10) 
Married 1.50 (0.87, 2.57) 1.12 (0.74, 1.69) 0.99 (0.60, 1.64) 1.03 (0.71, 1.47) 1.33 (0.89, 1.98) 1.31 (1.01, 1.70) 
Moderate PA
4
 0.82 (0.46, 1.46) 0.94 (0.65, 1.36) 1.05 (0.84, 1.32) 0.75 (0.54, 1.04) 0.94 (0.61, 1.47) 0.82 (0.59, 1.14) 
Alcohol Intake
5
 1.10 (0.61, 1.98) 1.47 (0.95, 2.25) 1.82 (1.07, 3.08) 0.83 (0.44, 1.57) 1.45 (0.90, 2.34) 1.06 (0.76, 1.49) 
Other drug use 1.48 (0.86, 2.58) 1.16 (0.52, 2.58) 0.63 (0.40, 0.99) 0.88 (0.61, 1.26) 1.02 (0.99, 1.04) 1.21 (0.78, 1.87) 
Rehabilitation 0.83 (0.37, 1.86) 0.67 (0.36, 1.25) 1.04 (0.54, 2.00) 0.94 (0.44, 2.01) 0.99 (0.18, 5.45) 0.67 (0.36, 1.27) 
1
Each year increase in use/smoking; 
2
Number of joints/cigarettes; 
3
Family Income-to-Poverty Ratio; 
4
At least moderate physical activity (recreational); 
5
Weekly. Bold values 
indicate signiﬁcance at alpha ::; 0.05. MJ, marijuana; SYN, syndrome; AO, abdominal obesity; HPT, hypertension; HYPGLY, hyperglycemia; HYPTRIG, hypertriglyceridemia; 
HDL, high density lipoprotein cholesterol. 
All odds ratios with 95% CI starting from 1 and not in bold are due to rounding and have p-values above 0.05. 
 
Table 3b 
Adjusted analysis for metabolic syndrome and components separately for cigarette smoking and marijuana use. 
 
Variable Cigarette use 
Odds ratio (95% CI) 
  Marijuana  use 
Odds ratio (95% CI) 
  
 (A) Years of smoking (B) Current  (A) Years of use (B) Regular user 
Metabolic syndrome 1.00 (0.09, 1.00) 1.17 (0.90,1.52)  1.05 (1.01, 1.09) 0.25 (0.06, 1.02)  
Abdominal obesity 1.01 (0.99, 1.03) 0.84 (0.55, 1.29)  1.03 (0.99, 1.07) 0.42 (0.13, 1.36)  
Hypertension 1.04 (1.01, 1.07) 0.67 (0.40, 1.11)  1.05 (1.02, 1.09) 0.26 (0.10, 0.67)  
Hyperglycemia 1.03 (1.01, 1.05) 0.71 (0.43, 1.08)  1.02 (0.98, 1.06) 0.50 (0.13, 1.89)  
Hypertriglyceridemia 1.04 (1.02, 1.06) 0.62 (0.46, 0.85)  1.03 (1.01, 1.06) 0.76 (0.15, 3.97)  
Low HDL cholesterolemia 1.00 (0.09, 1.00) 0.96 (0.77, 1.20)  1.02 (0.99, 1.05) 0.54 (0.18, 1.55)  
CI, conﬁdence interval; adjusted analysis is based on the model in Table 3a and shows only the odds ratios for respective dependent variables in the table for: Each year 
increase in smoking cigarette. Current smoker compared to non-smoker or former smoker. Each year increase in marijuana use. Regular marijuana user compared to non- 
regular or non-user. 
 
metabolic irregularities including abdominal obesity and insulin 
resistance [18–21]. In our research, basic examination character- 
istics show that, among the study participants, regular marijuana 
users had an average waist circumference higher (98.5 ± 1.4) than 
that for the general participants (97.8 ± 0.8). Research also shows 
that cigarette smoking causes inﬂammation which is a precursor for 
metabolic syndrome. Smoking increases the production of pro- 
cytokines, reduces levels of anti-inﬂammatory cytokines [22] and 
increases pathologic levels of inﬂammation-sensitive proteins like 
alpa1-antitripson, ﬁbrinogen, etc. [23]. In our study, by status, 
unadjusted analysis showed no signiﬁcant increase in odds for MetS 
among those who smoke cigarettes or those who use marijuana when 
compared to those who do not (Table 2). Current cigarette smokers, 
however, had 43.0% increase in odds for high blood pressure and 
61.0% increase for high serum triglycerides compared to nonsmokers. 
The relationship between metabolic syndrome and marijuana 
use or cigarette smoking appears to be associated with the years of 
use/smoking. Our results show signiﬁcant associations between 
years of marijuana use or cigarette smoking and metabolic 
syndrome as well as some of its components. This ﬁnding needs 
further investigation with respect to the duration of use or cutoff 
point that is likely to put one at the most disadvantage for 
metabolic abnormalities. In multivariate analysis, even though by 
cigarette smoking or marijuana use status the relationship may 
seem protective, we ﬁnd otherwise by duration of use. Each year of 
marijuana use was associated with a signiﬁcant 5.0% increase in 
odds of having metabolic syndrome and 4.0% increase in odds of 
having hypertension (Table 3a). Each year increase in   smoking 
cigarette also increases the odds of having hypertension by 3.0% as 
well as hyperglycemia by 3.0%. Separate models that concentrated 
on smoking alone or marijuana use alone yielded results that were 
similar (Table 3b). 
With respect to ﬁndings in existing research, marijuana users 
and cigarette smokers may be showing better metabolic proﬁles by 
status. However, the relationship between duration of use in this 
study draws our attention to a possible long-term adverse effect. 
For example in our model, marijuana users are 77.0% less likely to 
have metabolic syndrome, 69.0% less likely to have hypertension 
and 30.0% less likely have hypertriglyceridemia compared to non- 
users, however considering years of use, the relationship shows a 
higher odds for MetS and some of its components. This ﬁnding 
suggests that, the duration of marijuana use or smoking is an 
important factor in assessing metabolic health and that with 
prolonged years of use, the effects on metabolic health may be 
unfavorable. It is worth noting that we considered the effect of age 
transition on metabolic factor as well. 
Although the harmful effect of cigarette smoking on cardiovas- 
cular health is well known [24–27], the effect on some metabolic 
health factors is not deﬁnite [11,12] neither is that for marijuana 
use. Universal ﬁndings on this effect can have important 
implications for public health and chronic disease management. 
With respect to factors of metabolic syndrome, some research 
show that marijuana use is associated with lower insulin  levels 
[28] as well as less prevalence of diabetes among users and that 
it needs to be investigated in the management of diabetes [29]. 
Marijuana (cannabis) exerts its effect on the    endocannabinoid 
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system by acting on cannabinoid receptors. Cannabinoid receptors 
are stimulated by endocannabinoids that are endogenous ligands. 
Both cannabinoid receptor 1 (CB1) and receptor 2 (CB2) are 
involved in regulation of energy balance, appetite, insulin 
sensitivity and lipid metabolism [15,21,30,31]. Research on 
marijuana and metabolic syndrome is still geminating and without 
deﬁnite results. Research conducted by Penner et al. [28] based on 
a multiple linear regression model concluded that marijuana use 
was associated with lower levels of fasting insulin and lower waist 
circumference, with the inference that marijuana users may have a 
good glycemic proﬁle. A cross-sectional study by Muniyappa et al. 
[20] on the chronic effect of marijuana smoking on metabolic 
syndrome showed that those who smoke marijuana had a higher 
percent abdominal visceral fat, lower plasma HDL cholesterol, 
lower adipocyte insulin resistance index and lower percent free 
fatty acid (FFA) suppression during an oral glucose tolerance test 
(OGTT). A study by Thompson and Hay [32,33] questions the use of 
a linear regression in estimating this association and consequently 
recommend other analysis and models that consider factors 
endogenous to marijuana use. In our study we used logistic 
regression analysis and controlled for some factors endogenous to 
recreational substance like other drug use, rehabilitation, mar- 
riage, alcohol use, health insurance and income to poverty ratio. 
Available literature on smoking also shows that smoking has 
nonlinear relationships with factors of metabolic syndrome 
especially among moderate smokers,  but  heavy  smoking  of 
20 cigarettes or more daily leads to adverse levels of metabolic 
factors [11]. In this exploratory study we controlled for increasing 
quantity of cigarette or marijuana used. A near signiﬁcant 
reduction in abdominal obesity was found with increased quantity 
smoked. This relationship between smoking and weight or 
abdominal obesity has been demonstrated in some studies with 
varying results as well [34]. Even though reported bias may play a 
role, it is of interest to examine the effect of quantity of marijuana 
smoked in subsequent models because there is a biological basis 
between smoking and weight. Whilst considering years of 
marijuana use or cigarette smoking, the use of biological markers 
for smoking and marijuana use with cut offs might also be of 
importance in future studies to assess the causal effects of 
recreational substance use on metabolic health using longitudinal 
data. 
 
4.1.  Strengths and limitations 
 
A major strength of the study is the use of NHANES data. The 
NHANES has extensive and quality assured demographic, lifestyle, 
clinical and laboratory data for our purposes. The survey also 
embraces a large nationally representative sample. Our major 
limitation is the use of cross-sectional data as well as reported 
information which may be subject to recall or reporting bias. Also 
cross-sectional data ideally estimate associations and not causal 
relationships. However, for our exploratory purpose, the NHANES 
data is appropriate. Another main factor to consider in research on 
MetS is diet; however, we were unable to do so because the data 
were unavailable at the time of this study. As a proxy we included 
PIR, health insurance and education as a means of controlling for 
nutrition and health practices since income and education are 
highly associated with diet and healthy choices. It is worth noting 
that we assigned both past smokers and non-regular users a 
duration of zero recreational substance use. A way to quantify the 
years of use among past smokers and non-regular marijuana users 
would also help to better assess the association between duration 
of recreational substance use and metabolic syndrome. Another 
important factor could be the use of biological markers of 
recreational substance use. For example, Delta-9-tetrahydrocan- 
nabinol (THC) is a marker of marijuana use; however even though 
NHANES has data on cotinine as a marker for cigarette smoking, 
laboratory results on THC is yet to be available. 
 
5. Conclusion 
 
Increased years of marijuana use or cigarette smoking are 
associated with unhealthy levels of the components of metabolic 
syndrome among adults in the US. With the inclination for 
recreational marijuana use, this relationship may be considered 
critically to avert future metabolic complications. The duration of 
marijuana use or cigarette smoking is potentially an important 
factor in assessing metabolic health. With prolonged years of use, 
the effects on metabolic health might be unfavorable. We also 
found that marijuana use like cigarette smoking is also associated 
with hypertension. Our research seeks to add to the geminating 
interest in research on metabolic syndrome and marijuana use and 
cigarette smoking as an illuminating pathway to addressing 
recreational substance use and factors associated with cardio- 
metabolic diseases, a major cause of morbidity and mortality. 
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Introduction 
Marijuana is a psychoactive substance that induces relaxation and 
euphoria. Marijuana is classified as a schedule 1 drug by the drug 
enforcement administration (DEA) and is an illicit compound under 
federal law. However, by the end of election 2016, 28 states had 
legalized medical marijuana. Eight states and Washington DC also 
permit adult recreational marijuana use. Support for legalization of 
marijuana is on ascendancy [1]. Like cigarette, the main route of 
administration of marijuana is smoking and whereas the detrimental 
effect of tobacco/cigarette on cardiovascular health is established, that 
of marijuana is unknown. 
Metabolic syndrome (MetS) is a constellation of cardiovascular risk 
factors and is a condition associated with detrimental cardiovascular 
prognosis. Because cardiovascular disease (CVD) is a leading cause of 
mortality worldwide [2], the prevalence of metabolic syndrome may be 
an important determinant of the health status of a nation. The prevalence 
of metabolic syndrome generally increases with age. During the period 
2003 to 2012, metabolic syndrome prevalence in the United States (US) 
was about 18.0% among adults aged 20-39 years, 35.0% among adults 
aged 40-59 years and 46.7% among adults aged 60 years and above [3]. 
In 2012, an estimated 31.0% of all global deaths were due to CVDs [4]. 
Studies on tobacco and marijuana are inconclusive
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Abstract 
 
Objective: Research on marijuana use suggests a protective effect on metabolic syndrome. National Cholesterol 
Education Program, Adult Treatment Panel III, World Health Organization, European Group for the study of Insulin 
Resistance and International Diabetes Federation have different criteria for metabolic syndrome. Definitions of both 
marijuana use and criteria for metabolic syndrome may influence the observed effects. We examine the relationship 
of years of marijuana use with the four common definitions of metabolic syndrome. 
 
Method: This is a cross-sectional study of 3051 adults aged ≥ 20 years who participated in the National Health and 
Nutrition Examination Survey 2011-2012. Only participants who responded to the question, “Have you ever  even 
once used marijuana or hashish?” were enrolled. Using multivariate logistic regression, we estimated odds ratios for 
metabolic syndrome with each year of marijuana use. 
 
Results: Adjusted odds ratios (AOR) for having metabolic syndrome with each increase in year of marijuana use 
was 1.05 (95% CI: 1.02, 1.08) using National Cholesterol Education Program Adult Treatment Panel III (ATP III) 
criteria. Respective AOR using International Diabetes Federation (IDF) was 1.08 (95% CI: 1.04, 1.13) and 1.05 (95% 
CI: 1.04, 1.13) using World Health Organization (WHO) or European Group for the study of Insulin Resistance (EGIR) 
criteria. Using ATP III or IDF criteria, the adjusted odds ratio of having hypertension (AOR Hyp) for each year of 
marijuana use was 1.07 (95% CI: 1.03, 1.12). Using WHO criteria, AOR Hyp was 1.05 (95% CI: 1.01, 1.09) and 
1.08 (95% CI: 1.03, 1.12) using EGIR. All the applicable criteria show increased odds for abdominal obesity: AOR 
1.06 (95% CI: 1.00, 1.11) (ATP III), 1.09 (95% CI: 1.05, 1.14) (EGIR) or 1.07 (95% CI: 1.01, 1.13) (IDF). Adjusted odds 
ratio for having high oral glucose tolerance test levels was 1.12 (95% CI: 1.07, 1.18) using WHO and EGIR criteria. 
 
Conclusion: Irrespective of the criteria for metabolic syndrome, each year of marijuana use showed increased 
odds of having metabolic syndrome, hypertension or high oral glucose tolerance test levels. This increased odd is in 
contrast to most findings in literature. The small, yet consistent increase in odds for hypertension was slightly higher 
than that observed with cigarette smoking. Recreational marijuana use may be detrimental to cardiovascular health. 
A standardized definition of marijuana use will be relevant for further investigation. 
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on their associations with metabolic syndrome and its components [2,5]. 
Metabolic syndrome has varying criteria. National Cholesterol Education 
Program, Adult Treatment Panel III (ATP), World Health Organization 
(WHO), European Group for the study of Insulin Resistance (EGIR) and 
International Diabetes Federation (IDF) have different   criteria   for   
metabolic   syndrome.   Definitions   of    both 
marijuana use and criteria for metabolic syndrome may influence the 
observed effects. We examine the relationship of years of marijuana use 
with the four common definitions of metabolic syndrome. Our 
hypothesis is that the definition used for metabolic syndrome may 
change the estimates of the associations between marijuana use and 
metabolic syndrome. 
 
Variable Sample Size (%) Race 
  NHW NHB MA OHISP ASIANS ORACE 
Marijuana Use***        
Never 1427 (46.80) 33.78 42.86 61.09 58.72 73.30 33.56 
Non-regular 824 (27.03) 33.51 25.66 23.10 21.71 18.74 28.70 
Regular 798 (26.17) 32.7 31.48 15.81 19.57 7.60 40.74 
Cigarette smoking***        
Never 1807 (59.25) 48.43 63.26 64.13 62.63 74.94 55.56 
Past 510 (16.72) 20.49 11.74 19.15 19.22 13.11 14.81 
Current 733 (24.03) 31.09 25.00 16.72 18.15 11.94 29.63 
Gender*        
Male 1552 (50.87) 52.02 46.66 54.71 48.04 53.40 55.56 
Female 1499 (49.13) 47.98 53.34 45.29 51.96 46.60 44.44 
Marital Status***        
Married 1371 (44.94) 49.15 31.65 52.28 41.28 56.91 38.89 
Other 1680 (55.06) 50.85 68.35 47.72 58.72 43.09 61.11 
Country of Birth***        
USA 2154 (70.65) 95.06 89.91 41.77 26.79 19.67 80.56 
Other Countries 895 (29.35) 4.94 10.09 58.23 73.21 80.33 19.44 
Education***        
≤ High School Graduate 1172 (38.41) 33.42 38.97 69.6 52.31 19.44 29.63 
≥ Some College 1879 (61.59) 68.58 61.03 30.6 47.69 80.56 70.37 
Age groups (Years)**        
20-25 543 (17.80) 15.09 20.43 15.50 17.08 19.44 28.70 
Above 25 2508 (82.20) 84.91 79.57 84.50 82.92 80.56 71.30 
PIR***        
<1.00 753 (26.39) 24.91 31.12 30.95 30.15 15.56 27.18 
1.00 to 2.99 1048 (36.73) 36.02 36.93 42.52 43.13 29.16 38.83 
3.00 to 4.99 555 (19.45) 19.26 19.09 18.03 17.94 24.04 14.56 
>5.00 497 (17.42) 19.81 12.86 8.50 8.78 31.20 19.42 
Other Drug Use***        
No 2504 (82.23) 74.41 87.01 80.49 87.14 94.6 71.30 
Yes 541 (17.77) 25.59 12.99 19.51 12.86 5.40 28.70 
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Ever had rehabilitation***        
No 2877 (94.30) 92.54 92.18 97.57 96.44 99.30 92.59 
Yes 174 (5.70) 7.46 7.82 2.43 3.56 0.70 7.41 
 
Table 1a: Proportions of recreational substance use and demographic characteristics of participants stratified by race, Percentages are column 
percentages. Chi square tests (*P<0.05, **P<0.01, ***P<0.001) show significant differences among the various racial ethnic groups. MA: Mexican 
Americans; NHW: Non-Hispanic Whites; NHB: Non-Hispanic Blacks; OHISP: Other Hispanics; ORACE: Other Race or Multiracial; PIR: Family 
Income to Poverty Ratio. 
 
Literature Review 
Metabolic syndrome is a co-occurrence of hypertension, 
hyperlipidemia, hyperglycemia and visceral obesity. Metabolic 
syndrome is associated with cardiometabolic pathology [6]. There is no 
unified definition [7,8] for MetS, however, the definition by the National 
Cholesterol Education Program, Adult Treatment Panel III (ATP III) is 
widely adopted because of its clinical applicability [8]. In accordance 
with ATP III, MetS is a co-occurrence of any three of the following: 
Hypertension, hyperglycemia, abdominal obesity, reduced high density 
lipoprotein cholesterol (HDL-C) or hypertriglyceridemia. By WHO 
standard, MetS is a diagnosis of diabetes or increased two hour oral 
glucose tolerance test (OGTT) or fasting insulin levels plus any two or 
more of the following: hypertension, obesity, high plasma triglycerides, 
low plasma HDL-C or albumin creatinine ratio ≥ 30. By EGIR criteria, 
MetS consists of fasting insulin level above 75th percentile of cohorts, 
and two or more of the following: hypertension, abdominal obesity, 
hypertriglyceridemia or low HDL-C. The IDF criteria require increases 
in ethnicity-specific waist circumference and any two or more of the 
following: hypertension, hypertriglyceridemia, low plasma HDL-C and 
high fasting plasma glucose or diagnosis of diabetes [8]. 
Results from research on marijuana use and MetS suggest a 
protective effect of marijuana use for MetS and some of its components 
[5,9]. Although some therapeutic effects of extracts of cannabis 
(marijuana plant) can be anticipated [10], these benefits may not apply 
to recreational use of marijuana. In the US, tobacco and marijuana are 
the most common substances of abuse after alcohol [11]. Statistics from 
the 2014 National Survey of Drug Use and Health, under the Substance 
Abuse and Mental Health Services Administration, show that among 
US adults aged 18-25 years, the lifetime prevalence of alcohol, cigarette 
and marijuana use were 83.4%, 56.1% and 52.6%, respectively whilst 
among US adults aged 26 years and above, lifetime prevalence were 
88.3%, 67.5% and 46.1%, respectively [12]. With a likely increase in 
marijuana use arising from legalization of marijuana, it is important to 
assess the relationship with determinants of cardiovascular disease. 
 
Method 
 
Data and variables 
This is a cross-sectional study of adults aged 20 years and above who 
participated in the National Health and Nutrition Examination Survey 
(NHANES) 2011-2012. Only participants who responded to the 
question, “Have you ever even once used marijuana or hashish?” were 
enrolled. 
Dependent variable: Our main dependent variable was MetS. We 
used the four most widely accepted definitions of MetS. In accordance 
with 2005 modification of ATP III criteria for Mets, we classified 
participants as having MetS if they had a co-occurrence of three or more  
of  the  following:  Hypertension-an  average  blood      pressure 
>130/85 mm Hg or use of medication for hypertension; Hyperglycemia-
defined as fasting plasma glucose (FBG) ≥ 100 mg/dl or use of 
medication for diabetes; Abdominal obesity or high waist 
circumference-defined as females with waist circumference >88.0 cm 
and males with waist circumference >102.0 cm; Low HDL 
cholesterolemia-defined as plasma HDL-C levels <50 mg/dl for females 
and <40 mg/dl for males or use of medications for 
hypercholesterolemia; and Hypertriglyceridemia-defined as plasma 
triglycerides ≥ 150 mg/dl or use of medication for 
hypercholesterolemia. Details of laboratory and clinical procedures are 
described in the NHANES manual. 
By WHO criteria, participants who said they had been diagnosed 
with diabetes by a doctor or were using medications for diabetes, or had 
a two hour oral glucose tolerance test (OGTT) result 140 mg/dl, or 
fasting insulin levels >25.2 µIU/ml and had any two or more of the 
following: average blood pressure 140/90 mmHg; body mass index >30 
kg/m2; plasma triglycerides 150 mg/dl; plasma HDL-C levels <39 mg/dl 
(for females) or <35 mg/dl (for males); and albumin creatinine ratio 30. 
By EGIR criteria, participants whose fasting insulin level fell above 
75th percentile of this study group and had two or more of the following: 
average blood pressure ≥ 140/90 mm Hg or use of medications for 
hypertension; waist circumference ≥ 94 cm if male  or 
≥ 80 cm if female; plasma triglyceride ≥ 150 mg/dl; HDL-C ≥ 39 mg/dl. 
By IDF criteria, ethnicity-specific waist circumference being ≥ 94 cm 
(for black males) or ≥ 80 cm (for black females); ≥ 102 cm (for white 
males) or ≥ 88 cm (for white female), and ≥ 94 cm or ≥ 80 cm for males 
and females respectively who were Asians/Mexican American/ 
Multiracial and had any two or more of the following: average blood 
pressure>130/85 mmHg or on medication for hypertension; plasma 
triglyceride ≥ 150 mg/dl or on anti-cholesterol medications; plasma 
HDL-C ≤ 50 mg/dl (for females) or ≤ 40 mg/dl (for males); and fasting 
plasma glucose ≥ 100 mg/dl diagnosis of diabetes by a doctor. 
Main independent variable: According to the questions in NHANES, 
participants who had never used marijuana/hashish were categorized as 
never marijuana users. Those who said they had used marijuana/hashish 
but not up to once a month for more than a year were classified as non-
regular marijuana users and those who had used marijuana or hashish at 
least once a month for more than a year were classified as regular 
marijuana users. 
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We estimated years of marijuana use by subtracting each participant’s 
age at regular marijuana use from their current age. For participants who 
were non-regular users of marijuana, we assigned zero years of 
marijuana use. Our multivariate logistic analysis included 
only marijuana users (regular users or non-regular-users) to enable us 
assess the effect among those who had ever used marijuana and avoid 
placing non-regular marijuana users and never marijuana users on the 
same level. 
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Variable Diagnostic Criteria 
 WHO EGIR ATP III IDF 
Metabolic Syndrome     
Overall 9.21 8.55 23.17 23.37 
BY SUBSTANCE USE (Yes)     
Regular marijuana 8.40 8.40 20.93 21.3 
Current cigarette smoker 9.41 9.14 24.83 24.69 
BY RACE (Yes)     
NHW 9.43 9.97 24.71 22.01 
NHB 9.21 8.07 25.73 25.98 
MA 14.89 10.33 24.62 28.27 
OHISP 7.83 5.69 21.71 25.27 
ASIANS 5.39 6.79 15.46 18.03 
ORACE 8.33 6.48 18.52 19.44 
Hypertension     
Overall 10.56 23.89 31.69 31.69 
Hyperglycemia     
Overall 19.04 8.19 21.86 23.43 
Hyperinsulinemia     
Overall 3.61 61.42 - - 
High OGTT Level     
Overall 5.97 5.97 - - 
Hypertriglyceridemia     
Overall 11.67 11.67 18.49 18.49 
Low HDL-C     
Overall 10.49 15.34 34.81 34.81 
High WC     
Overall - 69.59 49.80 64.15 
NHW - - - 50.07 
NHB - - - 69.59 
ASIANS/MA/OHISP/OR - - - 74.57 
BMI >30 kg/m2     
Overall 35.59 - - - 
High Albumin/Creatinine Ratio     
Overall 13.27 - - - 
Table 1b: Prevalence in Percentages of Metabolic Syndrome Diagnosis and its Components by the Different Criteria. 
NHW: Non-Hispanic Whites; NHB: Non-Hispanic Blacks; MA: Mexican Americans; OHISP: Other Hispanics; ORACE: Other Race or 
Multiracial; OGTT: Oral Glucose Tolerance Test; HDL-C: High Density Lipoprotein Cholesterol; WC: Waist Circumference; BMI: Body Mass 
Index. 
 
 
Other independent variables: We included cigarette smoking. We 
classified participants who reported they have smoked at least 100 
cigarettes their entire life and still smoke every day or some days as 
current cigarette smokers. Those who have smoked at least 100 cigarettes 
but do not currently smoke at all were past smokers. Those who had never 
smoked cigarettes were non-smokers. Non-smokers or past smokers were 
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Figure 1: Graphs showing the relationship between components of 
metabolic syndrome and increasing years of marijuana use (Y-axis 
shows the respective fitted values of components of MetS). 
assigned zero years of smoking cigarettes. Years of smoking for current 
smokers was estimated by subtracting reported initial age at regular 
smoking from their current age. 
 
 
In the multivariate model, we controlled for age of participant, 
gender, race, education, marital status, poverty to income ratio (PIR), 
participation in at least moderate physical activity, days of alcohol use 
in a week, other recreational substance use (methamphetamine, heroin 
or cocaine) and participation in rehabilitation. Details of the 
measurement of these control variables are described in NHANES 
manual. 
 
Statistical analysis 
 
We used Stata/IC 14.0 software package for analysis. We estimated 
the proportions of demographic and clinical variables by race to have 
an appreciation of the differences. Disparities in socioeconomic factors 
as well as race/ethnicity have been described as important factors for 
metabolic abnormalities as well as recreational substance use [13,14]. 
Using logistic regression analysis, we estimated unadjusted and adjusted 
odds ratios for MetS among regular and  non-regular marijuana users. 
In all analyses we applied the appropriate weights for the NHANES 
multi-stage survey design and used a two-tailed significance level of 
α=0.05 (http://www.cdc.gov/nchs/data/nhanes/nhanes3/ 
cdrom/NCHS/MANUALS/WGT_EXEC.PDF). 
 
 
Results 
 
Demographic and metabolic syndrome characteristics of 
study participants 
 
Characteristics for the basic demographics and MetS with its 
components are shown in Tables 1a and 1b, respectively. Overall, 26.2% 
of participants were regular marijuana users and 24.0% were current 
cigarette smokers (Table 1a). Among the different racial/ethnic groups, 
people of other race/Multi-racials had the highest prevalence for 
marijuana use (40.7%) with Asians having the least (7.6%). Among all 
participants, the prevalence of other illicit drug use (cocaine, heroin or 
methamphetamine) was 17.7% whilst multiracial had the highest 
prevalence (28.7%). A higher proportion of Non-Hispanic Blacks 
(7.8%) have had rehabilitation compared to Multiracial (7.4%). 
 
 
Of the four criteria, ATP III and IDF classify more people as having 
MetS (23.2% and 23.4%, respectively) and WHO criteria classify the 
least (9.2%) and EGIR (8.6%) (Table 1b). This pattern is also seen for 
MetS prevalence among marijuana users and cigarette smokers: the 
proportion  of  MetS  among  marijuana  users  was  21.3%  (IDF) and 
20.9% (ATP III) whilst the proportion of MetS among cigarette smokers 
was 26.0% (IDF) and 25.7% (ATP III). By race/ethnicity, ATP III 
classifies the 25.7% of non-Hispanic Blacks as having MetS. All other 
criteria predominantly classify Mexican Americans (MA) as having 
MetS (28.3%-IDF, 14.9%-WHO and 10.3%-EGIR). 
Hypertension, hypertriglyceridemia, and Low HDL-C are more 
prevalent (31.7%, 18.5%, 34.8%, respectively) using ATP III and IDF 
criteria. The prevalence of hyperglycemia is 21.9% using ATP III and 
23.4% using IDF. Disparities in prevalence for other components are 
shown in Table 1b. 
 
 
 
Components of metabolic syndrome with years of marijuana 
use 
 
 
The relationship between components of MetS and years of 
marijuana use are shown in Figure 1. Curvilinear relationships  between 
years of marijuana use and components of MetS are apparent. The 
relationship of systolic blood pressure (SBP), diastolic blood pressure 
(DBP), waist circumference (WC), plasma triglycerides (TG) 
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and fasting blood glucose (FBG) with years of marijuana used tend to 
be J-Shaped. This shows an initial decrease in values but eventual 
increase. The relationship between plasma high density lipoprotein 
cholesterol HDL-C and years of marijuana used was U-shaped. This 
shows an initial decrease and eventual increase. 
 
Bivariate analysis of metabolic syndrome and its components 
with years of marijuana use and cigarette smoking 
By all the criteria, unadjusted analysis showed a universal increase 
in odds of having MetS with every year of marijuana use. With every 
year increase in marijuana use, the odds ratios (OR) for having MetS 
are 1.06 (95% CI: 1.03, 1.08) for ATP III, 1.06 (95% CI: 1.04, 1.08) for 
WHO, 1.05 (95% CI: 1.02, 1.08) for EGIR and 1.05 (95% CI: 1.03, 1.07) 
for IDF (Table 2a). By all applicable criteria, for each year of marijuana 
use, a significant increase in odds is observed for hypertension, 
hyperglycemia, high oral glucose tolerance test levels, 
hypertriglyceridemia, abdominal obesity and obesity. 
The relationship with cigarette use shows increases in odds for MetS 
which is only significant by ATP III. For hypertension, hyperglycemia 
and high OGTT levels a significant increase in odds is demonstrated by 
all the criteria (Table 2b). 
 
Multivariate analysis 
For every year of marijuana use, adjusted odds ratio (AOR) for 
having MetS (controlling for years of smoking, gender, age, marriage, 
education, country of birth, PIR, having health insurance, participating 
in at least moderate physical activity, weekly alcohol intake, other illicit 
drug use and undergoing rehabilitation) by ATP III and IDF criteria was 
1.05 (95% CI: 1.02, 1.08). By WHO, AOR was 1.08 (95% CI: 1.04, 
1.13) and by EGIR criteria, AOR was 1.06 (95% CI: 1.01, 1.11) (Table 
3a). 
Each year of marijuana use showed AORs for hypertension as: 1.07 
(95% CI: 1.03, 1.12) by ATP III and IDF, 1.05 (95% CI: 1.01, 1.09) by 
WHO and 1.08 (95% CI: 1.03, 1.12) by EGIR All the applicable criteria 
show increased odds for abdominal obesity: 1.06 (95% CI: 1.00, 1.11) 
by ATP III, 1.09 (95% CI: 1.05, 1.14) by EGIR and 1.07 (95% CI: 1.01, 
1.13) by IDF. For obesity the AOR was 1.03 (95% CI: 1.01, 1.06) 
according to WHO. The AOR for having a high oral glucose tolerance 
test level was 1.12 (95% CI: 1.07, 1.18) by WHO and EGIR. 
Every year increase in smoking cigarette by this model, was 
associated with AOR of 1.05 (95% CI: 1.01, 1.09) for hypertension by 
WHO criteria. For abdominal obesity, the AOR was 0.97 (95% CI: 0.95, 
0.99) by EGIR criteria (Table 3b). 
 
Discussion 
Duration of marijuana use seems to be a significant factor  associated 
with MetS. Its effect is small, but of the same order of magnitude or 
possibly greater than the effect of years of cigarette smoking. It must be 
noted that conventionally, cigarette smoking status has been used in 
analysis, but we attempted assessing the effect of years of smoking 
cigarette on MetS. Although current studies on marijuana use and MetS 
show a protective effect of marijuana on glycemic factors, this may be 
the result of not considering the years of using marijuana in cross 
sectional analysis. All criteria, demonstrate that every year increase in 
marijuana use is associated with at least 5% increase in odds of having 
MetS. In relation to components of MetS, a general increase in odds is 
observed with progress in years of using marijuana, however they vary 
by significance. 
 
 
Variable 
Diagnostic Criteria 
ATP III WHO EGIR IDF 
Metabolic Syndrome     
Marijuana use1 1.06 (1.03-1.08) 1.06 (1.04-1.08) 1.05 (1.02-1.08) 1.05 (1.03-1.07) 
Hypertension     
Marijuana use1 1.06 (1.03-1.09) 1.09 (1.04-1.15) 1.08 (1.04-1.11) 1.06 (1.03-1.10) 
Hyperglycemia     
Marijuana use1 1.04 (1.00-1.08) 1.04 (1.00-1.09) 1.04 (1.00-1.08) 1.04 (1.00-1.08) 
Hyperinsulinemia  
- 
   
- 
Marijuana use1 1.03 (0.98-1.08) 1.04 (1.00-1.07) 
High OGTT  
- 
   
- 
Marijuana use1 1.07 (1.05-1.10) 1.07 (1.07-1.10) 
Hypertriglyceridemia     
Marijuana use1 1.05 (1.03-1.07) 1.03 (1.01-1.06) 1.03 (1.01-1.08) 1.05 (1.03-1.07) 
Low HDL-C     
Marijuana use1 1.03 (1.00-1.06) 1.00 (0.97-1.03) 1.03 (1.00-1.05) 1.03 (1.00-1.06) 
Abdominal Obesity  -   
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Marijuana use1 1.03 (1.00-1.07)  1.07 (1.05-1.10) 1.03 (1.00-1.06) 
Obesity  
- 
  
- 
 
- 
Marijuana use1 1.03 (1.01-1.05) 
High Albumin/Creatinine Ratio -  - - 
Marijuana use1  0.99 (0.96-1.02)   
 
Table 2a: Unadjusted analysis of having metabolic syndrome and risky levels of components by the different criteria for each year of marijuana 
use, bold values indicate significance at α<0.05, Marijuana use1 - each year of marijuana use among regular or non-regular marijuana users. 
 
We observed different strengths in AORs for MetS with each year of 
marijuana use based on the different criteria for Mets, but the same 
direction of associations. Even though literature has discussed the 
possibility of a common definition for MetS [15-17], this suggests that 
the different criteria for metabolic syndrome may be comprehensive 
and can produce unified relationships with respect to marijuana use. 
This is irrespective of the fact that WHO and EGIR set predefined risk 
factors on glucose or insulin impairment. However, WHO and EGIR 
criteria, showed marked reductions in prevalence. This is primarily due 
to the prequalifying criteria for glucose/insulin impairment. 
 
 
Variable 
Diagnostic Criteria 
ATP III WHO EGIR IDF 
Metabolic Syndrome  
1.02 (1.01-1.05) 
 
1.02 (0.98-1.05) 
 
1.01 (0.99-1.04) 
 
1.01 (0.99-1.03) 
Cig smoking1 
Hypertension  
1.03 (1.00-1.06) 
 
1.07 (1.03-1.12) 
 
1.08 (1.04-1.11) 
 
1.03 (1.00-1.06) 
Cig smoking1 
Hyperglycemia  
1.02 (1.00-1.03) 
 
1.02 (1.00-1.04) 
 
1.04 (1.00-1.08) 
 
1.02 (1.00-1.03) 
Cig smoking1 
Hyperinsulinemia  
- 
 
1.03 (0.99-1.07) 
 
1.04 (1.00-1.07) 
 
- 
Cig smoking1 
High OGTT  
- 
 
1.02 (1.00-1.05) 
 
1.07 (1.05-1.10) 
 
- 
Cig smoking1 
Hypertriglyceridemia  
1.02 (1.01-1.04) 
 
1.03 (1.00-1.05) 
 
1.03 (1.01-1.06) 
 
1.02 (1.01-1.04) 
Cig smoking1 
Low HDL-C  
1.01 (0.99-1.02) 
 
0.97 (0.94-1.01) 
 
1.02 (1.00-1.05) 
 
1.01 (0.99-1.02) 
Cig smoking1 
Abdominal Obesity  
1.00 (0.98-1.02) 
 
- 
 
1.07 (1.05-1.10) 
 
1.00 (0.98-1.02) 
Cig smoking1 
Obesity  
- 
 
1.00 (0.98-1.02) 
 
- 
 
- 
Cig smoking1 
High Albumin/Creatinine Ratio  
- 
 
1.01 (0.99-1.03) 
 
- 
 
- 
Cig smoking1 
 
Table 2b: Unadjusted analysis of having metabolic syndrome and risky levels of components by the different criteria for every year of cigarette 
smoking, bold values indicate significance at α<0.05, Cig smoking1-each year of cigarette use among regular or non-regular marijuana users. 
 
Metabolic syndrome is a powerful tool for identifying people at risk 
for CVD and diabetes [15]. It is important that research on   marijuana 
 
J Addict Res Ther, an open access journal 
ISSN:2155-610 demonstrate the true 
relationship with MetS and it 
components. These findings could 
provide a behavioral path to 
Citation: Yankey BA, Rothenberg R, Strasser S, White KR, Okosun IS (2017) Relationship between Years of Marijuana Use and the Four Main 
Diagnostic Criteria for Metabolic Syndrome among United States Adults. J Addict Res Ther S11: 017. doi: 10.4172/2155-6105.1000S11-
017 
 
47 
 
preventive and therapeutic interventions for CVD and diabetes [15] in 
relation to marijuana use. 
Criteria of MetS is not settled, neither is the definition of marijuana 
use. Metabolic syndrome is a complex condition and there may be 
more factors intrinsic and extrinsic to MetS and marijuana use that 
need attention. This study finds that prolonged use of marijuana is a 
likely associated factor for MetS, glucose intolerance and hypertension. 
Increased years of marijuana use are also associated with 
hypertriglyceridemia but are significant using ATP III and IDF criteria. 
Even though all the criteria use a plasma triglyceride cut off ≥ 150 
mg/dl, WHO and EGIR do not account for the use of cholesterol 
lowering medications and this could be a factor in the difference in 
significance. The recreational use of marijuana may ultimately threaten 
public health gains in the area of cardiovascular disease prevention. A 
longitudinal study of the relationship between recreational marijuana 
use and MetS concerning clinical factors and biological markers for all 
the four core attributes of MetS: insulin resistance, visceral obesity, 
atherogenic dyslipidemia and endothelial dysfunction [15] are exigent. 
The active constituent of marijuana, delta-9-tetrahydrocanabinol 
(D-THC), acts on the endocannabinoid system (ECS), primarily   CB1 
receptors and CB2 receptors. The ECS plays a role in regulation of 
appetite and metabolism [18]. Modulation of the ECS affects the four 
core attributes of MetS [19]. These effects are being studied for 
management of obesity [20,21], dyslipidemia [21], atherosclerosis [22] 
and insulin resistance [20,23]. Cannabinoids or cannabis extracts may 
have therapeutic indications but, because absorption is erratic, the 
pharmacodynamics is still under active investigation for therapeutic 
purposes [24]. Arguments for recreational use of marijuana based on 
research for therapeutic use may need re-evaluation. 
In Figure 1, initial reductions in blood pressure and glucose values 
change to increases after about five years of use. This shows a probable 
eventual deleterious effect on blood pressure and glycemic levels. 
However, after about twenty years of using marijuana, low levels of 
HDL-C tend to increase, which may allude an ultimate beneficial effect 
on HDL-C. This further stresses the complex relationship between 
cannabinoids and metabolic processes. All the applicable criteria show 
that increased years of marijuana use is associated with abdominal 
obesity. Active investigation of marijuana in long term metabolic 
derangements is important. Criteria by IDF show higher odds for 
abdominal obesity than ATP III. This is because IDF uses racial-ethnic 
specific waist circumference. 
 
Variable ATP III WHO EGIR IDF 
Marijuana use1 1.05 (1.02, 1.08) 1.08 (1.04, 1.13) 1.06 (1.01, 1.11) 1.05 (1.02, 1.08) 
Cigarette smoking1 1.01 (0.98, 1.04) 0.99 (0.95, 1.04) 1.00 (0.96, 1.04) 1.00 (0.97, 1.03) 
Age 25+ 2.70 (0.66,11.10) 0.67 (0.12, 3.78) 0.92 (0.19, 4.45) 1.01 (0.37, 2.78) 
Males 0.78 (0.29, 2.09) 2.54 (0.98, 6.63) 1.29 (0.45, 3.64) 0.71 (0.27, 1.90) 
Asians 1.37 (0.18,10.19) 1.72 (0.27,10.82) 0.98 (0.19, 5.14) 1.41 (0.24, 8.19) 
Blacks 0.74 (0.33,1.66) 0.63 (0.13, 2.96) 0.59 (0.20, 5.08) 0.81 (0.36, 1.83) 
M Americans2 0.63 (0.22, 1.80) 1.54 (0.55, 4.27) 2.02 (0.96, 4.23) 1.16 (0.31, 4.28) 
Other Hispanics 0.22 (0.02, 2.55) 1.44 (0.33, 6.22) 1.01 (0.20, 5.08) 2.39 (0.40,14.24) 
Other Race 0.99 (0.22, 4.48) 0.89 (0.18, 4.46) 0.69 (0.20, 2.40) 1.45 (0.39, 5.47) 
Born in USA 3.87 (0.44,34.28) 3.04 (0.60,15.29) 4.08 (0.84,19.75) 5.53 (1.39,22.08) 
Education 0.97 (0.59, 1.59) 1.26 (0.94, 1.71) 1.39 (0.80, 2.40) 0.98 (0.61, 1.58) 
PIR3 0.93 (0.78, 1.10) 1.01 (0.65, 1.57) 0.91 (0.76, 1.09) 0.99 (0.81, 1.21) 
Insured 1.25 (0.68, 2.27) 0.52 (0.25, 1.04) 0.66 (0.38, 1.15) 1.00 (0.52, 1.93) 
Married 1.17 (0.53, 2.58) 0.83 (0.30, 2.33) 1.75 (0.63, 4.83) 1.78 (0.54, 2.58) 
Moderate PA4 1.17 (0.54, 2.51) 0.74 (0.31, 1.76) 0.85 (0.40, 1.79) 1.16 (0.53, 2.53) 
Alcohol Intake5 1.84 (1.10, 3.08) 0.74 (0.28, 1.99) 0.95 (0.52, 1.74) 1.69 (1.04, 2.74) 
Other drug use 0.92 (0.45, 1.89) 0.49 (0.21, 1.18) 0.39 (0.23, 0.64) 0.99 (0.46, 2.14) 
Rehabilitation 1.01 (0.44, 2.33) 1.33 (0.50, 3.57) 1.66 (0.58, 4.77) 1.23 (0.55, 2.72) 
 
Table 3a: Multivariate analysis of metabolic syndrome with years of marijuana use by different criteria controlling for cigarette smoking and other 
variables, 1-Each year increase in marijuana use or cigarette smoking; 2-Mexican American; 3-Family Income-to-Poverty Ratio; 4-At least 
moderate physical activity (recreational); 5-Weekly, bold values indicates significant at α<0.05; ATP III-National Cholesterol Examination Panel, 
Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF: International Diabetes Federation; WHO: World Health 
Organization. 
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In this study, non-significant varying relationships are  observed with 
each year of cigarette smoking and the different criteria for MetS. This 
relationship could be explained by the combination of non- smokers and 
past smokers. For marijuana use, all participants had at least used 
marijuana before. The association of cigarette smoking status with 
hypertension is established knowledge [25,26]. Increased years of 
cigarette smoking was also associated with increased odds for high 
OGTT levels (WHO and EGIR). Research has shown that diabetic 
patients who continue to smoke have uncontrolled glucose levels even 
with treatment [27]. Studies have long shown that nicotine from 
cigarette smoking impairs glucose metabolism [28-30] and reflects as 
high proportions of glycated hemoglobin, high OGTT and high fasting 
insulin [31,32]. 
Strengths and limitations 
Demographic, lifestyle, clinical, laboratory parameters and a large 
nationally representative sample was obtained from NHANES data, 
however this cross-sectional study estimates associations not risks. 
Marijuana use was self-reported and the study may have a reporting bias 
especially with information on illicit substance use as marijuana. We 
initially controlled for the quantity of marijuana used but this did not 
significantly affect the results and was excluded from the model. 
 
 ATP III WHO EGIR IDF 
Hypertension  
Marijuana use1 1.07 (1.03, 1.12) 1.05 (1.01, 1.09) 1.08 (1.03, 1.12) 1.07 (1.03, 1.12) 
Cigarette smoking1 1.02 (0.98, 1.05) 1.05 (1.02, 1.09) 1.02 (0.99, 1.05) 1.02 (0.98, 1.05) 
Hyperglycemia  
Marijuana use1 1.02 (0.98, 1.07) 1.02 (0.98, 1.07) 1.02 (0.98, 1.07) 1.02 (0.98, 1.07) 
Cigarette smoking1 1.00 (0.97, 1.03) 1.00 (0.97, 1.03) 1.00 (0.97, 1.03) 1.00 (0.97, 1.03) 
Hyperinsulinemia  
Marijuana use1 - 1.01 (0.92, 1.11) 1.04 (0.99, 1.11) - 
Cigarette smoking1 - 1.00 (0.97, 1.03) 1.00 (0.96, 1.04) - 
High Oral Glucose Tolerance Test 
level 
 
Marijuana use1 - 1.12 (1.07, 1.18) 1.12 (1.07, 1.18) - 
Cigarette smoking1 - 0.99 (0.96, 1.03) 0.99 (0.96, 1.03) - 
Hypertriglyceridemia  
Marijuana use1 1.04 (1.00, 1.07) 1.02 (0.98, 1.05) 1.02 (0.98, 1.05) 1.04 (1.00, 1.07) 
Cigarette smoking1 1.01 (0.99, 1.03) 1.01 (0.98, 1.05) 1.01 (0.98, 1.05) 1.01 (0.99, 1.03) 
Low HDL-C     
Marijuana use1 1.03 (0.99, 1.07) 1.02 (0.98, 1.07) 1.04 (0.99, 1.08) 1.03 (0.99, 1.07) 
Cigarette smoking1 0.99 (0.97, 1.02) 0.97 (0.92, 1.02) 0.98 (0.93, 1.03) 0.99 (0.97, 1.02) 
Abdominal obesity  
Marijuana use1 1.06 (1.00, 1.11) - 1.09 (1.05, 1.14) 1.07 (1.01, 1.13) 
Cigarette smoking1 0.99 (0.97, 1.02) - 0.97 (0.95, 0.99) 0.95 (0.95, 1.01) 
Obesity by (BMI)  
Marijuana use1 - 1.03 (1.01, 1.06) - - 
Cigarette smoking1 - 0.99 (0.97, 1.01) - - 
High Albumin/ Creatinine ratio  
Marijuana use1 - 0.96 (0.91, 1.01) - - 
Cigarette smoking1 - 1.01 (0.97, 1.05) - - 
 
Table 3b: Multivariate analysis of components of metabolic syndrome with each year of marijuana use and cigarette smoking by different criteria 
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We did not control for diet, an important factor for MetS, however, 
we controlled for factors important in dietary and health decisions as 
income to poverty ratio (PIR), alcohol use, physical activity, health 
insurance and education. For ethnic-specific waist circumference by 
IDF, we classified NHBs as Europids based on ancestral genesis [33] 
that the ancestry of Blacks or African-American are predominantly 
Niger-Kordofanian (~71%), European (~13%) or other African (~8%) 
populations [34]. All NHWs were classified using values for Americans 
since distinctions based on the ethnic classification were unavailable. 
We however controlled for place of birth to possibly account for these 
differences. 
 
Conclusion 
 
Irrespective of the criteria for metabolic syndrome, each year of 
marijuana use showed increased odds of having metabolic syndrome, 
hypertension or high oral glucose tolerance test levels. Extended 
duration of marijuana use could possibly increase the risk for the 
development of metabolic syndrome. Longitudinal studies can show 
this risk. Irrespective of the criteria for MetS, we estimated increased 
odds of MetS with each year marijuana use. This may constitute an 
important pathway between marijuana use and cardiovascular disease 
in later life. The impact of duration of marijuana use should be 
considered in assessing the relationships with MetS. 
 
Longitudinal research is required to define the true relationship 
between marijuana use and metabolic syndrome. If a cardiovascular risk 
is established, a good understanding of the pathogenesis of metabolic 
syndrome and metabolic pathways of marijuana metabolites should be 
laid out. This will help address any risk factors which may initiate and 
facilitate CVD progression among marijuana users. 
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CHAPTER 4. 
 
Effect of marijuana use on cardiovascular and 
cerebrovascular mortality: a study using the NHANES linked 
mortality file 
Abstract 
 
Background: Reports associate marijuana use with cardiovascular emergencies. Studies relating 
marijuana use to cardiovascular mortality are scarce. Recent advance towards marijuana use legalization 
emphasizes the importance of understanding relationships between marijuana use and cardiovascular 
deaths; the primary ranked mortality. Recreational marijuana is primarily smoked; we hypothesize that 
like cigarette smoking, marijuana use will be associated with increased cardiovascular mortalities. 
Design: Mortality follow-up. 
 
Method: Data from 2011 public-use linked mortality file of National Center for Health Statistics, Centers 
for Disease Control and Prevention was used. Participants were aged 20 years and above, and responded 
to questions on marijuana use during the 2005 National Health and Nutrition Examination Survey. Only 
participants eligible for mortality follow-up were included. We conducted cox proportional hazards 
regression analyses to estimate hazard ratios for hypertension, heart disease and cerebrovascular mortality 
due to marijuana use. We controlled for cigarette smoking and other relevant variables. 
Results: Seventy-two and five-tenths percent of the 1213 eligible participants were presumed to be alive. 
The total follow-up time was 19,569 person-years. Adjusted hazard ratios for death from hypertension 
among marijuana users compared to non-marijuana users was 3.42 (95% CI: 1.20, 9.79) and for each year 
of marijuana use was 1.04 (95% CI: 1.00, 1.07). 
Conclusion: From our results, marijuana use increases the risk for hypertension mortality. Increased 
duration of marijuana use is associated with increased risk of death from hypertension. Recreational 
marijuana use potentially has cardiovascular adverse effects which needs further investigation. 
Key words 
 
THC, marijuana, cannabis, hypertension, cardiovascular mortality 
 52 
 
 
Introduction 
 
Cardiovascular diseases (CVDs) rank first as cause of mortality worldwide and most are 
preventable 1. Cardiovascular mortality encompasses death from diseases, emergencies or conditions 
associated with heart and blood vessels 2. In 2013, one out of every four deaths in United States (US) was 
due to heart disease (HD), stroke or other CVDs 3. Cardiovascular death rates have been declining in US 
since year 2000 4 due to clinical and public health interventions including smoking cessation. Irrespective 
of this decline 5, CVDs retain their lead as cause of mortality globally. Lifestyle modification including 
smoking cessation, physical activity, healthy diet, maintaining normal body mass index, and avoidance of 
harmful alcohol use reduce cardiovascular morbidity and mortality 6-8. 
Reports associate marijuana use with cardiovascular emergencies. Marijuana like cigarette is 
primarily smoked but contrary to marijuana, mortalities from CVDs due to cigarette smoking has been 
studied extensively 9-11. Recent advance towards legalization of marijuana in US, necessitates the 
determination of its association with cardiovascular mortality. The active constituent of marijuana, Delta- 
9-tetrahydrocannabinol (THC), accounts for some cardiovascular effects of marijuana 12, 13. Marijuana 
smoking increases heart rate from 20-100% for about two to three hours 14, causes postural hypotension, 
fainting, ischemic stroke and disruption of cardiac functions 12, 15, 16. We hypothesize that similar to 
cigarette smoking, recreational marijuana will be associated with increased cardiovascular mortalities. 
Methods 
 
We merged results of interviews in 2005 National Health and Nutrition Examination Survey 
(NHANES) with 2011 public-use linked mortality file of the National Center for Health Statistics 
(NCHS), Centers for Disease Control and Prevention (CDC) 17, since NHANES participants were 
interviewed on marijuana use starting 2005. The NHANES assesses the health and nutritional status of 
civilian noninstitutionalized US population. About 5000 nationally representative participants are selected 
through complex, multistage probability sampling yearly. Interviews are conducted by physicians and 
other healthcare professionals in participant’s homes and examinations conducted in a mobile center. 
Mortality information on participants in NCHS public-use linked mortality file is obtained from death 
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certificates or probabilistic matching from the National death index (NDI). Causes of death occurring in 
US before 1999 were based on the 9th revision of International Statistical Classification of Diseases, 
Injuries, and Causes of Death (ICD-9) guidelines and subsequently recoded into comparable ICD-10 
rubrics, as cause of deaths occurring from 1999 are coded on the 10th (ICD-10) revision. Deaths are 
classified as due to diseases of the heart (001), malignant neoplasms (002), chronic lower respiratory 
disease (003), accidents-unintentional injuries (004), cerebrovascular diseases (005), Alzheimer’s diseases 
(006), diabetes mellitus (007), influenza and pneumonia (008), nephritis, nephrotic syndrome and 
nephrosis (009) and all other causes (010) with another coding for hypertension and diabetes deaths. 
Those assumed alive, ineligible for follow up, or with cause of death unavailable are left un-coded. 
 
We selected participants eligible for mortality follow up, aged 20 years and above who answered 
“yes” or “no” to the question, “Have you ever used marijuana or hashish?” Participants who answered yes 
were classified marijuana users and those who answered no, as non-marijuana users. Duration of 
marijuana use was estimated by subtracting participant’s age at marijuana use initiation from the age at 
2005 screen. Follow-up period for eligible participants was 1991-2011. This study collectively refers to 
marijuana use, cigarette smoking and alcohol use as substance use. Participants who reported having 
smoked at least 100 cigarettes in their lifetime and still smoke were classified current smokers, with those 
who have ceased smoking as past-smokers. Those who never smoke nor smoked 100 cigarettes in lifetime 
were classified non-smokers. High-risk drinking is defined in dietary guidelines for Americans 2015-2020 
as consumption of four or more drinks any day or eight or more drinks weekly for women (five or more 
drinks any day or 15 or more drinks weekly for men). Participants who confirmed ever having five or 
more drinks almost every day at a point in life were classified as alcohol users. Participants reported their 
age, gender, educational status and race/ethnicity and prior diagnosis of hypertension, angina, congestive 
heart failure, heart attack or stroke by a doctor or other health professional. 
Statistical Analysis 
 
We estimated mortality rates and hazard ratio (HR) with 95% confidence intervals from Cox 
proportional hazards regression, for hypertension, heart disease and cerebrovascular deaths among 
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marijuana users and current cigarette smokers. Our main independent variables were marijuana use status 
and years of marijuana use. We controlled for cigarette smoking (non-smokers as reference), gender 
(female as reference), age ( 25 years and below as reference), race/ethnicity (Non-Hispanic Whites as 
reference), having health insurance (not having health insurance as reference), alcohol use (not having 
had five drinks or more on some days in life as reference), diagnosis of hypertension (no diagnosis of 
hypertension as reference) or CVD: angina, heart attack, congestive heart failure or coronary heart disease 
(no diagnosis of CVD as reference), education and body mass index (BMI), were controlled using 
continuous increasing level. Age was dichotomized as 25 years and below, or above 25 years. Research 
shows the age cut off point associated with illicit substance use, smoking and heavy alcohol consumption 
is 25 years 18. Interaction factor between smoking status and marijuana use status was not significant in 
the survival model, so the interaction factor was excluded. We estimated cumulative hazard for 
hypertension, heart and cerebrovascular disease mortality by marijuana use or cigarette smoking status 
over the 20 year period of follow up. Nelson-Aalen curves estimate cumulative hazard functions of 
censored data 19. The follow-up was right censored at the end of 2011. 
Results 
 
Demographic characteristics, marijuana use and cigarette smoking 
 
Total eligible participants were 1213 with one observation ending on or before entry and 72.5% 
presumed alive. Person-years follow up was 19,569. Average age at entry of participants was 37.7±11.2. 
Average BMI for all participants was 29.0±7.0, for marijuana users, 28.6±7.1 and for cigarette smokers, 
27.7±6.9. Demographic distribution is shown in Table 1. Among all 1213 participants, 34.3% neither use 
marijuana nor smoke cigarettes, 20.9% use only marijuana, 20.0% use marijuana & smoke cigarettes, 
15.6% use marijuana & are past-smokers, 4.8% are past-smokers and 4.4% smoke only cigarettes. 
Average duration of marijuana use was 11.5±12.8 years and 10.1±13.8 years for cigarette smoking. 
 
Diagnosis of hypertension or other cardiovascular diseases 
 
Twenty and a third percent of marijuana users compared to 20.6% of non-marijuana users had 
prior diagnosis of hypertension. Among current smokers, 21.8% had prior diagnosis of hypertension 
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compared to 23.4% of past-smokers and 18.7% of never smokers. Prevalence for prior diagnosis of any 
other CVDs was 3.8% among marijuana users and 3.6% for non-marijuana users, 6.1% for current 
smokers, 5.7% past-smokers and 1.9% for never smokers. Distribution of hypertension, heart and 
cerebrovascular mortality is shown in Table 1. 
Mortality incidence rates and ratios 
 
For all-cause mortality among marijuana users, incidence rate ratio was 1.29 (95% CI: 1.03, 1.61) 
and among current smokers 1.16 (95% CI: 0.90, 1.48). Mortality incidence rates by marijuana use and 
cigarette smoking stratified by cause of death are shown in Table 2. 
Unadjusted and adjusted hazard ratios 
 
Unadjusted hazard ratio for hypertension mortality among marijuana users compared to non- 
marijuana users was 1.86 (95% CI: 0.95, 3.66). Unadjusted HRs are shown in Table 3. For HD mortality, 
unadjusted HR was 1.21 (95% CI: 0.76, 1.92) among marijuana users compared to non-marijuana users 
and 1.01 (95% CI: 0.99, 1.03) for each year of marijuana use. For cerebrovascular disease mortality, all 
unadjusted HRs were non-significant for marijuana use and cigarette smoking (not shown in Table). 
Adjusted HRs for hypertension mortality among marijuana users compared to non-marijuana 
users was 3.42 (95% CI: 1.20, 9.79), and for each year of marijuana use was 1.04 (95% CI: 1.00, 1.07) 
(Table 3). All adjusted HRs for HD and cerebrovascular mortality showed non-significant estimates in 
this model for marijuana use and cigarette smoking in this model most likely due to sample size. Adjusted 
HR for HD mortality was: a) 1.09 (95% CI: 0.63, 1.88) for marijuana users compared to non-marijuana 
users and b) 1.00 (95% CI: 0.98, 1.02) for each year of marijuana use (Not shown in Table). 
Cumulative Hazard Curves 
 
Nelson-Aalen cumulative hazard estimates show that marijuana users have a higher risk for 
hypertension mortality than non-marijuana users (Figure 1A). For hypertension mortality, there are more 
flattened areas for smokers; non-smokers seem to have a higher risk. Cumulative hazard for all-cause 
mortality is higher among marijuana users and cigarette smokers than their counterparts (Figure 1B). 
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Discussion 
 
Marijuana users had an increased risk of hypertension mortality even after controlling for prior 
diagnosis of hypertension. Opiates have more deleterious consequences on the cardiovascular system than 
marijuana 20, but hypertensive crisis following marijuana use has been described 21, also cases of cardiac 
infarction and stroke following marijuana use among normotensives and people lacking history of 
cardiovascular diseases have however been described 21-23. Increase in risk for hypertension, HD or 
cerebrovascular disease mortality associated with cigarette use was not significant, largely due to the 
small sample size (n < 30) of mortalities among cigarette smokers under investigation. The hazardous 
effect of cigarette smoking on cardiovascular system has however been largely demonstrated in studies 9 
and is established knowledge. Also, our study focuses on marijuana use, and initial selection criteria was 
based on responses to marijuana use among adults. Our assumption that marijuana use or cigarette 
smoking continues throughout the period of follow up, may not be so. Taking into consideration the 
availability of smoking cessation programs, these behaviors may change with time, from participation in 
an intervention. Specific marijuana use cessation interventions are yet to be documented. Also use of 
cocaine/heroin/methamphetamine or participation in rehabilitation was not statistically relevant in our 
model and was excluded. We however controlled for relevant demographic factors. The observed large 
confidence intervals for marijuana use estimates can also be attributed to sample size. 
Within our limitations, our results however support a possible increased risk of mortality from 
CVDs related to marijuana use. Taking into consideration results of study by Aronow, W.S. and J. 
Cassidy 24, it is possible that the cardiovascular risk associated with marijuana use and prolonged years of 
marijuana use is even greater than the risk already described for cigarette use in studies. 
Delta-9-Tetrahydrocannabinol (THC) acts primarily on the endocannabinoid system which 
regulates behavior, metabolism and cardiovascular function. The endocannabinoid system consists of 
neuro-modulatory lipids (primarily the endogenous cannabinoid anandamide and 2-arachidonylglycerol), 
their metabolites and cannabinoid receptors CB1 and CB2. Cannabinoid receptors are distributed in the 
central nervous system, cardiovascular system and peripheral tissues. Cannabinoids including the 
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phytocannabinoid THC, exert sympathetic stimulation. Delineated cardiovascular effects of THC are 
increased heart rate, increased supine blood pressure, orthostatic hypotension 14, increased cardiac output, 
reductions in left ventricular ejection time16 and increases in venous carboxyhemoglobin levels24 which 
cause unhealthy cardiovascular and cerebrovascular outcomes. 
The 2020 goal of American heart association is to improve cardiovascular health of all Americans 
by 20%, and reduce mortality from CVDs and stroke by 20%.  Public health and clinical interventions 
have helped to promote the life’s simple seven indicators of good cardiovascular health: blood pressure 
control, increased physical activity, healthy diet, total cholesterol control, healthy weight, blood glucose 
control and smoking cessation which contributes to plummeting age standardized death rates from CVDs 
since 2009 25. Smoking is still the leading cause of preventable disease and death, and since recreational 
marijuana is primarily smoked, its use may contribute to increases in morbidities and mortalities. Factors 
of interest include effects of marijuana use on cardiovascular mortality among the youth and people with 
existing chronic conditions. The youth, especially those aged 18-25 years are more liable to substance use 
26 and adults are more likely to live with chronic conditions. This expands the demographic coverage of 
poor health consequences of marijuana use. In the interest of individual health, population health and 
lowering costs associated with healthcare, education on the adverse effects of recreational marijuana use 
should be a priority as recommendations and advancements are made towards its legalization. 
Conclusion 
 
Marijuana use increases the risk of hypertension mortality. Longer years of marijuana use 
increases risk of death from hypertension. This cardiovascular risk associated with marijuana use, may be 
greater than the cardiovascular risk already established for cigarette smoking. We are not disputing the 
possible medicinal benefits of standardized cannabis formulations; however, recreational use of marijuana 
should be approached with caution. It is possible that discouraging recreational marijuana use may 
ultimately impact reductions in mortality from cardiovascular causes. A purposeful longitudinal study 
modeled with inclusion of listed relevant limitations is recommended. 
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Table 1: Sociodemographic characteristics of participants, showing overall prevalence (%) and 
mortality rates (%) from hypertension, heart diseases and cerebrovascular disease. 
 
 
 
Variables Participants 
Total 
Mortality HBP HD CBV 
 
 Sample % Sample % % % 
Age ≤ 25years 226 18.6 63 9.5 22.2 11.1 
Age >25years 987 81.4 269 12.6 23.0 6.3 
Total 1213 100.0 332 12.1 22.9 7.2 
Male 550 45.3 168 8.3 23.2 4.8 
Female 663 54.7 164 15.9 22.6 9.8 
Total 1213 100.0 332 12.1 22.9 7.2 
Non-Hispanic Whites 579 47.7 162 14.8 26.5 7.4 
Non-Hispanic Blacks 286 23.6 76 7.9 19.7 10.5 
Mexican Americans 246 20.3 63 7.9 22.2 3.2 
Other Hispanics 45 3.7 11 27.3 18.2 0 
Other Race 57 4.7 20 10.0 10.0 10.0 
Total 1213 100.0 332 12.1 22.9 7.2 
< 9th grade 89 7.3 20 15.0 30.0 5.0 
9th - 11th grade 166 13.7 43 7.0 20.9 9.3 
High school graduate 277 22.9 76 7.9 21.1 7.9 
Some College/Associate degree 394 32.5 112 15.2 19.6 8.0 
≥ College graduate 286 23.6 81 13.6 28.4 4.9 
Total 1212 100.0 332 12.1 22.9 7.2 
Marijuana users 686 56.5 204 13.7 22.5 7.4 
Non-marijuana users 527 43.5 138 9.4 23.4 7.0 
Total 1213 100.0 332 12.1 22.9 7.2 
Current cigarette smokers 296 24.4 89 10.1 15.7 9.0 
Past-cigarette smokers 248 20·4 74 14.9 27.0 9.5 
Non-cigarette smokers 669 55.2 169 11.8 24.8 5.3 
Total 1213 100.0 332 12.1 22.9 7.2 
Alcohol use 190 17.7 55 10.9 29.1 7.3 
No Alcohol use 882 82.3 243 11.1 22.6 6.2 
Total 1072 100.0 298 11.1 23.8 6.4 
 
HBP, Hypertension HD, Heart Disease CBV, Cerebrovascular disease 
Note: Mortality rates shown are row percentages based on total mortality but do not add up to 100% 
because mortality rates of other diseases are not shown. 
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Table 2: Incidence estimates for mortality from hypertension, heart disease and cerebrovascular 
disease by substance use among study participants 
 
 
 
Cause of mortality Marijuana  
Hypertension 
Incidence rate in exposed/1000 
 
2.57 
 
Incidence rate in unexposed/1000 1.39  
Incidence rate in population/1000 2.04  
Incidence rate ratio 1.85 (0.92, 4.00) 
Attributable fraction in exposed 46.0%  
Attributable fraction in population 32.1%  
Heart disease 
Incidence rate in exposed/1000 
 
4.22 
 
Incidence rate in unexposed/1000 3.47  
Incidence rate in population/1000 3.88  
Incidence rate ratio 1.22 (0.75, 2.00) 
Attributable fraction in exposed 17.8%  
Attributable fraction in population 10.8%  
Cerebrovascular Disease 
Incidence rate in exposed/1000 
 
1.37 
 
Incidence rate in unexposed/1000 1.04  
Incidence rate in population/1000 1.23  
Incidence rate ratio 1.32 (0.54, 3.43) 
Attributable fraction in exposed 24.4%  
Attributable fraction in population 15.2%  
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Table 3: Unadjusted and adjusted analysis showing hazard ratios for hypertension mortality 
among (a) marijuana users and (b) each year of marijuana use 
 
 
 
Substance use and demographic 
factors 
Unadjusted hazards ratio 
(95% Confidence interval) 
Adjusted hazards ratio 
(95% Confidence interval) 
A) 
Marijuana user 
 
1.86 (0.95, 3.66) 
 
3.42 (1.20, 9.79)* 
Current smoker 1.06 (0.48, 2.33) 1.06 (0.40, 2.77) 
Former smoker 1.56 (0.75, 3.25) 1.33 (0.57, 3.10) 
Alcohol user 1.03 (0.43, 2.50) 0.95 (0.37, 2.45) 
Body mass index 1.03 (1.00, 1.08)* 1.05 (1.01, 1.10)* 
Age >25years 1.29 (0.54, 3.08) 1.25 (0.42, 3.67) 
Education 1.19 (0.90, 1.57) 1.00 (0.70, 1.43) 
Male 0.67 (0.35, 1.29) 0.72 (0.35, 1.49) 
Blacks 0.51 (0.21, 1.24) 0.42 (0.14, 1.27) 
Mexican Americans 0.49 (0.19, 1.28) 0.91 (0.28, 2.94) 
Other Hispanics 1.58 (0.48, 5.25) 2.51 (0.54, 11.63) 
Other Race 0.92 (0.22, 3.89) 1.23 (0.29, 5.35) 
Have health insurance 2.66 (1.04, 6.79)* 2.24 (0.75, 6.72) 
Diagnosed with hypertension 0.86 (0.38, 1.93) 0.81 (0.32, 2.06) 
Diagnosed with a CVD 2.18 (0.67, 7.06) 1.94 (0.42, 8.97) 
B) 
Each year of marijuana use 
 
1.03 (1.00, 1.05)* 
 
1.04 (1.00, 1.07)* 
Current smoker 1.06 (0.48, 2.33) 1.14 (0.43, 3.01) 
Former smoker 1.56 (0.75, 3.25) 1.35 (0.57, 3.20) 
 
 
 
CVD, Cardiovascular disease (angina, heart attack, congestive heart failure or coronary heart disease) 
Note: In Model A, hazard ratios are estimated based on substance use status, In Model B based on each 
year of marijuana use controlling for the same variables in Model A 
*P<0.05 
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A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Nelson-Aalen cumulative hazard estimate of mortality from (A) hypertension and (B) all- 
causes associated with marijuana use and cigarette smoking. Y-axis shows cumulative hazard rate 
and X-axis shows follow-up time. 
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CHAPTER 5.  
 
Summary of three studies 
 
Smoking seems to find a way of sustaining its popular social practice despite evidence of its 
detrimental effects on health. After several years of use, the deleterious effect of tobacco on health 
and economic growth cannot be overstated and the impact of public health measures towards 
smoking cessation and successes cannot be understated. The current inclination towards legalization 
of marijuana questions the possibility of a replay of the journey with tobacco. 
The use of marijuana in adults is also increasing especially among adults aged 25 years and 
above. Schedule I substances under the Federal Controlled Substances Act (CSA) are considered as 
having a high potential for abuse and not having any currently accepted medical use in treatment, 
consequently its use is reserved for very limited circumstances. The current move towards 
reclassification of marijuana as a legal substance places an urgent call to investigate the relationship of 
marijuana with cardiovascular diseases; the number one cause of morbidities and mortalities. 
In our first study, we assessed the relationship between marijuana use, cigarette smoking and 
metabolic syndrome (as well as components of metabolic syndrome) among adults in the United 
States, with emphasis on marijuana use. Our hypothesis was that in the United States, adults who use 
marijuana or/and tobacco are more likely to have unhealthy levels of the factors of metabolic 
syndrome and ultimately metabolic syndrome. We conducted multiple logistic regression analyses 
using data from the 2011–2012 United States National Health and Nutrition Examination Survey 
(NHANES). We classified metabolic syndrome using the definition by National Cholesterol Education 
Program, Adult Treatment Panel III (NCEP, ATP III) 2004 modification, which adapts the International 
Diabetes Federation (IDF) definition for hypertension and diabetes. The ATP III criteria is commonly 
used because of its clinical applicability. We estimated odds ratios for metabolic syndrome and its 
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components among participants who reported that they have smoked marijuana regularly for at least 
a year and still use marijuana. We also estimated odds ratios for metabolic syndrome and its 
components among current smokers. In the multivariate model, we included years of marijuana use 
and years of cigarette smoking and adjusted for factors endogenous and exogenous to marijuana use 
and relevant to metabolic syndrome: age, gender, race/ethnicity, education, income to poverty ratio, 
having health insurance, marriage, physical activity, alcohol use, use of other substances of abuse, 
participation in rehabilitation, joints of marijuana used and cigarette packs smoked. We estimated 
increased odds ratios for metabolic syndrome (OR 1.05; 95% CI: 1.01, 1.09), and hypertension (OR 
1.04; 95% CI: 1.01, 1.07) with each year of marijuana use. We also estimated increased odds ratios for 
hypertension (OR 1.03; 95% CI: 1.00, 1.06) and hyperglycemia (OR 1.03; 95% CI: 1.01, 1.05) with each 
year of cigarette smoking. Consistent with research, those who reported using marijuana showed a 
decrease odd ratio for metabolic syndrome (OR 0.23; 95% CI: 0.06, 0.90) compared to those who do 
not use marijuana. The finding that years of marijuana use is increases the odds for metabolic 
syndrome and hypertension stresses a possible factor that has been missed in assessing the marijuana 
use with metabolic syndrome. In separate analysis among those who smoke cigarette and those who 
use marijuana compared to their counterparts, this increase in odds ratios was still evident, and there 
was also an increased odds ratio for hypertriglyceridemia with each year of marijuana use (OR 1.03; 
95% CI: 1.01, 1.06) and each year of cigarette use (OR 1.04 (1.02, 1.06). 
Because metabolic syndrome has different criteria, in our second study, we assessed the 
relationship between metabolic syndrome and marijuana use based on the four common criteria by 
National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III), World Health 
Organization (WHO), European Group for the study of Insulin Resistance (EGIR), and International 
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Diabetes Federation (IDF). The different criteria used could also impact the results of the relationship 
between metabolic syndrome and marijuana use. Our hypothesis was that the definition used for 
metabolic syndrome may change the estimates of the associations between marijuana use and 
metabolic syndrome. We estimated the prevalence of marijuana use and cigarette smoking by race 
and conducted multiple logistic regression to estimate odds ratios. In the multivariate model, we 
controlled for age, gender, race, education, marital status, income to poverty ratio (PIR), participation 
in at least moderate physical activity, days of alcohol use per week, other recreational substance use 
(methamphetamine, heroin or cocaine) and participation in rehabilitation. Each year increase in 
marijuana use showed increased odds ratios for metabolic syndrome by all the four criteria: 1.05 (95% 
CI: 1.02, 1.08) using National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria, 
1.08 (95% CI: 1.04, 1.13) using International Diabetes Federation (IDF) and 1.05 (95% CI: 1.04, 1.13) 
using World Health Organization (WHO) or European Group for the study of Insulin Resistance (EGIR) 
criteria. Each year of marijuana use, showed increased odds ratio for hypertension for all the criteria: 
1.7 (95% CI: 1.03, 1.12) using ATP III or IDF criteria, 1.05 (95% CI: 1.01, 1.09) using WHO criteria, and 
 
1.8 (95% CI: 1.03, 1.12) using EGIR criteria. The ATP III, EGIR and IDF criteria for metabolic syndrome 
include increased waist circumference (abdominal obesity) in defining metabolic syndrome. All the 
criteria showed increased odds ratios for abdominal obesity: 1.06 (95% CI: 1.00, 1.11) for ATP III, 1.09 
(95% CI: 1.05, 1.14) for EGIR and 1.07 (95% CI: 1.01, 1.13) for IDF. The World Health organization and 
European Group for the study of Insulin Resistance have oral glucose tolerance test as part of the 
components for metabolic syndrome. Each year of marijuana use was associated with increased oral 
glucose tolerance test levels; OR 1.12 (95% CI: 1.07, 1.18). We also fitted residuals of each component 
of metabolic syndrome (systolic blood pressure, diastolic blood pressure, waist circumference, plasma 
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glucose, serum triglycerides and serum high density lipoprotein cholesterol) with years of marijuana 
use. This graphs showed an initial decrease in values but eventual increase in systolic blood pressure 
(SBP), diastolic blood pressure (DBP), waist circumference (WC), plasma triglycerides (TG) and fasting 
blood glucose (FBG) with progress in years of marijuana use. However, the relationship between 
plasma high density lipoprotein cholesterol (HDL-C) and years of marijuana used showed an initial 
decrease and eventual increase. 
Metabolic syndrome is associated with increased risk for cardiovascular morbidities and 
mortalities. With our estimates of increased odds of metabolic syndrome relative to duration 
marijuana use, we assessed the relationship of marijuana use with cardiovascular mortality. We used 
data from 2011 public-use linked mortality file of National Center for Health Statistics, Centers for 
Disease Control and Prevention and linked them to participants aged 20 years and above who 
responded to questions on marijuana use during the 2005 National Health and Nutrition Examination 
Survey and were eligible for mortality follow-up. Because recreational marijuana is primarily smoked; 
our hypothesis was that: like cigarette smoking, marijuana use will be associated with increased 
cardiovascular mortalities. We conducted cox proportional hazards regression analyses to estimate 
hazard ratios for hypertension, heart disease and cerebrovascular mortality due to marijuana use. We 
controlled for cigarette smoking, alcohol use, age, education, gender, race, having health insurance, 
diagnosis of a cardiovascular disease (angina, congestive heart failure, heart attack or stroke) or 
hypertension. Marijuana use increased the risk for hypertension mortality. Adjusted hazard ratios for 
death from hypertension among marijuana users compared to non-marijuana users was 3.42 (95% CI: 
1.20, 9.79) and for each year of marijuana use was 1.04 (95% CI: 1.00, 1.07). 
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Results of our study consistently show that marijuana use is associated with metabolic 
syndrome and detrimental cardiovascular health. Increased years of marijuana use was associated with 
increased odds of hypertension, increased values of systolic and diastolic blood pressures as well as 
increased risk for hypertension mortality. Contrary to research that marijuana use may be safe, our 
research shows that prolonged use of marijuana is associated with detrimental cardiovascular health. 
The endocannabinoid system plays an important role in metabolic regulation and current studies 
should explore the pathways associated with cardio-metabolic function and health. 
Our research is primarily cross sectional and exploratory, but the results point to the urgency 
and importance of investigating the relationship between marijuana use and cardio-metabolic health 
for the benefit of the public who believe that recreational marijuana use is probably not harmful to 
health, especially during an era where marijuana legalization is gaining support. 
 
 
Public health significance of study 
 
Metabolic syndrome is an emerging public health problem which may reach global epidemic 
levels because of changing lifestyles towards a more westernized lifestyle. Smoking is a major lifestyle 
associated with cardiovascular problems and hence metabolic syndrome. It is projected that metabolic 
syndrome may overtake smoking as a known risk factor for cardiovascular problems especially heart 
diseases. With the increasing support for legalizing marijuana use, it is important to demonstrate the 
relationship of marijuana with metabolic syndrome. If marijuana is found to be a risk factor for 
components of metabolic syndrome and cardiovascular disease at the same magnitude as cigarette 
smoking or even more, public health gains in cardiovascular disease prevention stand threatened. This 
is especially dependent on the likelihood of increased marijuana use with its legalization. 
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Metabolic syndrome can be controlled with healthy lifestyle. Even though the focus has been 
on healthy diet and participation in physical activity, smoking cessation should be an integral part of 
metabolic syndrome management. If marijuana use is found to have detrimental effect on metabolic 
activity and cardiovascular health, it will be important to develop intervention plans to reduce 
recreational marijuana use. The management and control of metabolic syndrome requires the effort of 
individuals at risk, families, communities, health care providers and health care systems. 
The goal of healthy people 2020 on substance use is to reduce substance abuse to protect the 
health, safety, and quality of life for all, especially children (Health et al., 2000). Substance use has a 
major impact on the quality of life, on families, on communities, on nations and on health systems. 
Substance use especially marijuana use is on the ascendancy among adults. Increasing age is already 
an independent factor for several chronic diseases and coupling this with the detrimental effects of 
substance use can pose a significant health burden. Substance use carries economic, social, mental 
and public health problems. In 2005, about 22 million Americans had a drug use or alcohol problem 
with 95% of them unaware of their drug use or alcohol problem. About 24.8% of those who know their 
problem and seek treatment are not successful at obtaining treatment. 
Heart disease, stroke and other cardiovascular disease, are highly prevalent in the United 
States and pose significant economic and health burden. The goal of healthy people 2020 for 
cardiovascular health is to improve cardiovascular health and quality of life through prevention, 
detection, and treatment of risk factors for heart attack and stroke. This includes early identification 
and prompt treatment of heart attacks and strokes, interventions to prevent repetition of 
cardiovascular events and ultimately reduction in cardiovascular mortalities. Risk factors listed as 
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modifiable for cardiovascular disease are high blood pressure, high cholesterol, diabetes, unhealthy 
diet, physical inactivity, overweight and obesity and cigarette smoking. 
Evidence suggests that, rates of cardiovascular morbidity and mortality among the US 
population would decline significantly with major interventions on, and improvements in lifestyle 
concerning diet, physical activity, control of high blood pressure and cholesterol, appropriate aspirin 
use and smoking cessation with emphasis on bridging disparities (Barr, 2016) . 
Healthy people 2020 aims increase overall cardiovascular health in the US population, reduce 
coronary heart disease and stroke mortalities, reduce the proportion of persons in the population with 
hypertension, reduce the proportion of adults with high total blood cholesterol levels and mean levels 
of total blood cholesterol among the population, increase the proportion of adults who are advised by 
health care providers on cholesterol lowering management, healthy lifestyles as well as use of aspirin 
where indicated for people with elevated low density lipoprotein cholesterol. Healthy People 2020 
aims to reduce the disease burden of diabetes mellitus and improve the quality of life for all persons 
who have, or are at risk for diabetes mellitus. Some objectives towards this goal relevant to our study 
include reducing the annual number of new cases of diagnosed diabetes in the population and 
reducing the rates of cardiovascular deaths among people diagnosed with diabetes. The association of 
marijuana use with hyperglycemia in our study makes marijuana use an important indicator of the 
rates of incident diabetes which needs further investigation. If this relationship is established, 
education on the harms of marijuana to glycemic factors and subsequent interventions to reduce 
incidence of diabetes through reductions in rates of marijuana use will be relevant. 
Our research seeks to raise awareness of the health impact on the co-occurrence of these 
factors among populations and the detrimental effects it can cause on health, and to document the 
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urgency of investigating the relationship of recreational marijuana use among populations with 
cardiovascular morbidity and mortality. The finding that increasing years of marijuana use is associated 
with increased odds for metabolic syndrome and mortality from hypertension is an observation that 
calls for urgent investigation to delineate the mechanisms underlying marijuana use and cardiovascular 
health, especially among a nation with increasing support for legalization of marijuana use. About one 
in every three adults in the US has hypertension and only about 50% of them have their blood pressure 
under control (S. S. Yoon, Carroll, & Fryar, 2015). 
Primary prevention methods for sustaining cardiovascular health are highly effective. Stressing 
on lifestyle changes to improve and preserve cardiovascular health is a major activity of public health. 
Prevention efforts on substance use which carry cardiovascular risk are thus very important. Some of 
the Healthy People 2020 objectives towards reducing substance use include: increasing the proportion 
of adolescents aged 12 to 17 years who perceive great risk with substance abuse, increasing the 
proportion of adolescents who disapprove of trying marijuana or hashish once or twice by ten percent, 
increase the proportion of persons who received specialty treatment for abuse or dependence in the 
past year from 16% as 2008 to 17·6% by 2020 among those who need alcohol and/or illicit drug 
treatment, and to reduce illness, disability, and death related to tobacco use and secondhand smoke 
exposure. 
The objectives on substance use prevention are strongly related to the constructs of social 
cognitive theory; the theoretical basis for explaining substance use. It is important that the populace 
build a solid cognitive disposition on substance use based on the information available on its effects 
on health especially during the early years of life. This can help improve self-efficacy and ultimately 
prevent the use of substances that can be detrimental to health. With increase in the prevalence of 
substance use 
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among adults, it is important the education on substance use is targeted toward adults as well, 
especially those who already have existing chronic diseases. 
Demonstrating the true effects of recreational substance use (especially those that are easily 
accessible and seem harmless) on health will help prevent substance use and protect the health of 
the public. The framework for ending tobacco use epidemic outlined by Healthy People 2020 can be 
applied to marijuana use prevention if research establishes marijuana use as detrimental to health. 
Policies as outlined for tobacco prevention may include comprehensive marijuana-free policies, 
abstinence and cessation programs on marijuana use and access to these programs, hard-hitting 
anti marijuana media campaigns, funding for marijuana control programs and research, measures of 
controlling access to marijuana based on its eventual decriminalization, and limiting advertising and 
promotion aimed at adolescents. 
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Appendices 
 
 
Figure 1.1 Measurement of independent variable (marijuana use) 
 
 
 
 
 
 
Figure 1.2 Measurement of independent variable (cigarette smoking) 
‘‘Have you ever 
used marijuana?’’ 
Yes 
‘‘Have you smoked marijuana or hashish at least 
once a month for more than a year?’ 
No 
(Never marijuana 
users) 
Yes 
(Regular 
marijuana users) 
No 
(Non-Regular 
marijuana users) 
‘‘How old 
were you the first time you 
used marijuana or hashish?’’ 
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Figure 2.1 Definition of metabolic syndrome by four common criteria 
 
Chart adapted from Scott M. Grundy, James I. Cleeman, et al., AHA/NHLBI Scientific Statement: Diagnosis 
and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and 
Blood Institute Scientific Statement Circulation. 2005;112:17 2735-2752 
 
ALB/CR – Albumin creatinine ratio 
ATP (III) – National Cholesterol Education Program Adult Treatment Panel III 
BMI – Body mass index 
EGIR – European Group for the Study of Insulin Resistance 
FPI – Fasting plasma Insulin 
HDL-C – High density lipoprotein cholesterol 
IDF – International Diabetes Federation 
IFG – Impaired fasting glucose 
IGT – Impaired glucose tolerance 
LIS – Low insulin sensitivity 
T2DM – Type 2 diabetes mellitus 
TG – Triglycerides 
OGTT – Oral glucose tolerance test 
WHO – World Health Organization 
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Figure 3.1 Chart showing selection of participants for merging and mortality follow-up 
 
 
 
 
Figure 3.2 Distribution of participants by substance use 
 
